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Melanomas are heterogeneous tumors comprised of distinct cell subtypes that collectively 
form a single ‘organ.’ Failure to effectively target genetic diversity within this malignant organ 
underlies stalled tumor regression. This is referred to as resistance, wherein the tumor organ or 
microenvironment (TME) no long shrinks in response to therapy. Instead, invasive melanomas 
outgrow and secrete signals to alter the TME thereby promoting progression and dissemination. 
This inflammatory process shares many features in common with wound healing, and chronic 
inflammation has become an emergent hallmark of cancer. This dissertation establishes that 
transforming growth factor-β (TGFβ) release is an essential mediator of the persistent 
inflammation in the TME. In response to therapeutic stress, melanoma is shown to upregulate 
expression of pro-inflammatory cytokines and TGFβ. These molecules concomitantly antagonize 
the stroma leading to the activation of gene networks associated with wound healing and epithelial-
to-mesenchymal transition (EMT). Here, TGFβ ligands are shown to transmit signals to fibroblasts 
to promote transformation into contractile myofibroblasts, referred to as cancer associated 
fibroblasts (CAF). These α-smooth muscle actin (αSMA+) CAFs transiently accumulate in wounds 
and sites of chronic inflammation. Within these inflamed sites CAFs secrete and synthesize 
‘wound-associated’ extracellular matrix (ECM) which blunt the anti-tumor response to therapies. 
Dysregulated ECM promotes drug resistance via growth factor binding (e.g. TGFβ) and cell-ECM 
signaling that promotes invasion of dense tissue melanoma spheroids. Here, matricellular tumor-
ECM is shown to contain the matrikine tenascin-C (TNC). Tenascin-C has been experimentally 
 v 
shown to bind epidermal growth factor receptor (EGFR), promote malignant invasion, and 
promote motility and survival. Cocultures therapy inflamed melanomas are shown to stoke 
(αSMA+) CAFs. Clinically relevant inhibitors of the TGFβ receptor were used to perturb TGFβ 
signaling between the tumor-and-stroma. This led to the suppression of CAF transformation and 
limited in vitro outgrowth of melanoma via drug sensitization to mitogen-activated protein kinase 
(MEK) inhibitors. In vivo, a combination strategy to inhibit TGFβ activation of mouse CAFs 
results in MEK suppression of melanoma outgrowth and limits metastasis. Thus, combined 
targeting of the tumor-and-stroma limits cytotoxic cell stress and CAF remodeling of the inflamed 
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1.0  Introduction 
The diagnosis of melanoma continues to increase in frequency and is readily curable in 
early-stage cutaneous disease. Roughly nine in 10 of the more than one million individuals with 
melanoma will survive.  However, survival is drastically reduced following dissemination (5-year 
survival rate of 22%, SEER). While there has been significant progress in the detection and 
treatment of melanoma, the most effective cure remains surgical resection. Inoperable metastatic 
disease accounts for nearly all melanoma-related deaths and is virtually incurable. Advances in the 
understanding of melanoma plasticity and the progression from healthy to pathological tissues that 
form the tumor microenvironment (TME) have offered new insights toward developing more 
effective therapeutic strategies.  
1.1 The Metastatic Cascade  
Persistent exposure to environmental and genetic insult drives melanocyte transformation 
into malignant melanoma. These localized and even regional sites of disease are curable if detected 
and removed. However, progression leading to dissemination often results in the formation of 
intractable metastases with dismal prognoses. In metastatic disease, disseminated melanomas 
escape the primary tumor and immune surveillance, transit the vasculature, and colonize ectopic 
tissues. This highly inefficient process will persist if a small fraction of escaped cells successfully 
enters into spontaneous quiescence or dormancy in the ectopic tissue (Fidler JI et al., 2003; 
Talmadge JE et al. 2010; Hanahan D & Weinberg RA 2000, 2011). These minimal residual 
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melanomas remain dormant, however transient, prior to an inflammatory stimulus that promotes 
the emergence of metastatic disease (Figure 1).    
 
 
Figure 1: Schematic of melanoma dissemination and colonization 
Skin Inflammation: Chronic environmental damage (UV) coupled with DNA damage and mutations drive 
cellular death and the release of damage associated proteins (DAMPs). These bioactive signals recruit 
myeloid derived cells (immune infiltration) to clear apoptotic cells. Immune intravasation drives 
inflammation mediated by cytokines, chemokines, and proteolytic cleavage of extracellular matrix. 
Vertical Invasion: Stromal fibroblasts are inflamed as melanoma invades along a tenascin-C (TNC) front, 
during dissolution of the skin basement membrane. Therapeutic treatment to halt progression drives 
reciprocal signaling and TLR4 driven immunosuppression. A pro-tumorigenic therapy induced secretome 
promotes ECM deposition and a matrisome that promotes angiotropism and escape from the primary tumor. 
Circulating melanoma cells transit the vasculature to ectopic organs. Metastatic Disease: Small fractions 





Metastasis is still the predominant cause for most cancer-related deaths – despite clinically 
confirmed remission or cure (Chaffler et al., 2011). The establishment of metastatic melanoma is 
ominous as frontline treatments such as checkpoint inhibitors quickly lose efficacy in comparison 
to responsive primary lesions (Balch CM et al. 2009). A major obstacle for the eradication of 
melanoma is tied to the genetic basis of individual clones, which can be grouped into multiple 
genetic subtypes (BRAF, RAS, NF1 and Triple Wild type). Mutant BRAF tumors typically contain 
amplifications of melanocyte inducing transcription factor (MITF) and BRAFV600E, which is 
present in roughly half of melanomas. Mutant RAS tumors are typified by activation of mitogen-
activated kinases (MAPK) and serine/threonine kinase (AKT) pathways, which is often activated 
in response to therapeutic targeting. Mutant NF1 tumors occur in aged patients and often show 
high mutational burden, while triple wild-type tumors exhibit copy number variations (CNV) 
indicative of mutational events but paradoxically lack an ultra-violet (UV) signature (Cancer 
Genome Atlas Network, 2015). Treating these tumors is therefore complex. Single-cell RNA 
sequencing revealed that a majority of melanomas contain multiple subtypes within single lesions 
(Tirosh I et al. 2016). Thus, FDA approved inhibitors vemurafenib, dabrafenib, and trametinib 
which target these genetic drivers often display a strong initial response that is seldom durable in 
terms of the overall response rate (ORR) with relapse within ~5-7 months and eventual death 
(Gadiot J et al., 2013; Haferkamp S et al. 2013; Hauschild A et al., 2012; Lee JT et al., 2010; 
McArthur GA et al., 2013). Reduced therapeutic penetrance is common in metastatic melanoma 
despite effective regression of the primary tumor. This paradigm is likely linked to the incomplete 
understanding of how metastatic tumors coevolve within distinct microenvironments to acquire 
resistance (Wagle N et al., 2011; Van Allen EM et al., 2014). 
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1.2  The tumor microenvironment promotes progression 
Melanoma is non-cell autonomous and requires hospitable microenvironments for 
progression and survival. Our foundational model views tumors as an organ wherein cancer 
survival is driven by modifications in cell and extracellular matrix (ECM) signaling. The TME is 
comprised of non-malignant stromal and immune cells, ECM, and signaling molecules. This 
cellular ecosystem generates heterotypic interactions to support cancer proliferation, invasion, and 
drug resistance (Junttila MR et al. 2013; Qain BZ et al., 2010; Joyce J et al., 2009; Kalluri R 
et al., 2006; Egebald M et al., 2010). In this regard the TME is vital for progression to lead to 
metastasis. Reciprocal stromal and cancer signaling can activate cancer intrinsic epithelial-to-
mesenchymal transition (EMT) and removal of stromal cells from the TME results in a loss of 
immunosuppressive gene expression (Yang et al., 2008; Tirosh I et al., 2016). This suggests that 
bidirectional signaling in the TME is essential for the stepwise progression of melanomas from 
low-to-high grade malignancies.   
1.2.1  The complicated biological origins of CAFs 
Of the several possible cell-cell interactions in the TME, few precede melanomas and 
cancer associated fibroblasts (CAFs). CAF signaling manifests via cell-cell contacts, adhesion 
molecules, and signaling factors such as growth factors, cytokines chemokines, ECM, MMPs, 
protease inhibitors, and lipids (Ruiter D et al., 2002; Píerard GE et al., 2012; Werner W et al., 
1997).  The precise origin of CAFs is unknown though the most likely source is suspected to derive 
from tissue resident fibroblasts. However, transdifferentiation of pericytes or bone marrow derived 
mesenchymal cells (MSCs) have not been excluded despite the necessity to first undergo 
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endothelial /- epithelial-to-mesenchymal (Endo-/ EMT) (Gascard P et al., 2016; Kullari R, 2016; 
Xiao et al., 2015). CAFs are morphologically distinct in comparison the spindle-like normal 
counterpart. CAFs appear larger with more focal adhesions and exhibit enhanced proliferative and 
migratory capacity to epigenetic and protein expression (De Wever, O et al., 2008; Saadi, A. et 
al., 2010; Ma, XJ et al., 2009). Thus, the inherent lack of CAF ontogeny lends to the complexity 
of these heterogeneic stromal populations. Consequently, a plethora of signaling pathways have 
been implicated in CAF conversion and activation. 
1.2.2  Signals that awaken the tumor stroma 
The TME is replete with growth factors and paracrine signals which can functionally 
activate fibroblast conversion to CAFs. Of the many potential candidates, transforming growth 
factor-β (TGFβ) has been implicated as a central player in the development of CAFs. The TGFβ 
superfamily consists of TGFβ1, 2, and 3 which bind to the cognate serine/threonine protein kinase 
TGFβ receptor (TGFβR type I/II) to augment the phosphorylation of intracellular SMAD 
transcription factors. Activated SMADs then transit the cytosol to form SMAD complexes which 
ultimately localize to the cell nucleus and bind hundreds of genomic loci to drive transcriptional 
activation or repression (Figure 2) (David CJ et al., 2018). 
Transforming growth factor-β has multiple contextual roles in wound healing and fibrosis 
which are relevant to CAF activation, though whether TGFβ is tumor suppressive or promoting 
remains controversial. Co-implantation of breast-tumor xenografts with resident tissue-matched 
fibroblasts resulted in healthy fibroblast conversion to CAFs. This transformation was driven by 
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autocrine TGFβ and stromal cell-derived factor 1 (SDF-1) signaling loop (Kojima Y et 
  
Figure 2: The TGFβ signaling pathway 
In the basal state (LEFT), TGFβ is sequestered in the extracellular matrix (ECM) in a latent inactive state, 
while the serine/threonine transmembrane type I/II TGFβ receptors exist as inactive monomers (allosteric 
inhibition). Mothers against decapentaplegic homologue (SMAD) proteins in the cytoplasm (SMAD 1, 2, 
3, 5, 8) cycle as inactive monomers while SMAD4 transits in-and-out of the nucleus. (RIGHT) Upon 
activation, ligands are released in the tissue microenvironment (allosterically by integrins) and bind TGFβ 
receptors to form ligand-receptor complexes with type II receptor activation type I subunits by 
phosphorylation. Activated type I/II receptor complexes phosphorylate SMADs which phosphorylate and 
from heterotrimer complexes with SMAD4 (R-SMADs). Nuclear localized SMAD complexes bind to 
hundreds of genomic loci activating transcription factors to initiate transcription. Inhibitory cofactors drive 
degradation of R-SMADs to end transcription in the nucleus while inhibitory SMADs block phosphate 
from binding the receptor complexes in the cytoplasm. Ubiquitin (Ub) is recruited to shuttle SMADs for 
proteasomal degradation. Receptor dissociate and return to basal state in the absence of ligand activation. 
Modified figure reproduced from (David CJ et al., 2018).  
 
al., 2010). CAFs have also been shown to reciprocally drive EMT in breast cancer via TGFβ-
SMAD signaling, while SDF-1 which maintains the CAF phenotype, is reported to enhance breast 
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cancer invasion and migration (Yu, Y et al., 2014; Al- Ansari, MM et al., 2013).  However, the 
release of TGFβ is not exclusive to fibroblasts. This begs the question of sources of TGFβ in the 
TME and how expression may differ among subtypes of melanoma populations. Normal 
fibroblasts, presumably lacking activation of TGFβ-SDF1, are reported to suppress tumor growth 
(Chen X et al., 2018). This well-established paradigm is bi-directional. Co-engraftment studies 
with CAFs expressing TGFβ is reported to drive human mammary epithelial cell hyperplasia 
whereas inoculation with normal fibroblasts resulted in tumor stasis (Kuperwasser C et al., 2004; 
Picard O et al., 1986). Despite these foundational studies, there is a lack of clarity surrounding 
the mechanisms of whether TGFβ is pro-tumorigenic, which is exemplified by a study reporting 
that TGFβRII suppression in CAFs led to tumor expansion (Busch, S. et al., 2015). Therefore, 
TGFβ signaling in CAFs and how this impacts melanoma progression is still open ended.  
1.2.3  CAF are foundational in cultivating the TME  
The presence of pro-inflammatory cytokines, growth factors and exosomes within the TME 
converge to drive fibroblast transformation into hypercontractile myofibroblasts. Upon 
transformation, CAFs release a bioactive secretome and exhibit a greater synthetic capacity, which 
combine to promote progression and reshape therapeutic responses (Sahai E, et al., 2020; Bhome, 
R. et al. 2017).  
The epigenetic and microenvironmental activation of CAFs drives the release of multiple 
matrix metalloproteases 1, 2, 3, 9, 12, 19 (MMPs), protease inhibitors (TIMPs), in addition to a 
host of tumor supportive chemo-and-cytokines (e.g., abbrev., TGFβ, EGF, FGF, VEFA, PDGF, 
HGF and IL6) which have pivotal roles in cultivating the TME (Kullari R, 2016). The potency of 
these molecules is typified by hepatocyte response to non-malignant release of IL6, which was 
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shown to drive a pro-metastatic niche in the liver; the most common metastatic site (Lee JW et 
al., 2019). This is particularly salient given that physiologic stress, such as an invading tumor, has 
the potential to trigger fibroblast release of IL-6 and Activin A (TGFβ family) (Fordyce, CA et 
al., 2010, 2014).To expand, production of vascular endothelial growth factor (VEGF) endows 
CAFs with pro-angiogenic capacity (O’Connell, JT et al., 2011), MMPs to promote ECM 
remodeling, epidermal growth factor to promote tumor invasion and cell motility (Grahovac et 
al., 2014), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) to stimulate 
CAF proliferation, and  the synergistic signaling of  hepatocyte growth factor (HGF) combined 
with TGFβ, IL6 to promote drug resistance to BRAFV600E and EGFR inhibition (Kumari N et al., 
2016; Wilson TR et al., 2012; Wang W et al, 2009; Straussman R et al., 2012). Interestingly, 
the CAF secretory phenotype is largely maintained in vitro in the absence of the tumor and TME 
(Orima et al., 2005).  However, refined genetic analysis of CAFs outside of the TME have 
revealed that pro-tumorigenic gene networks are lost (Tirosh et al., 2016). This implies the 
importance of establishing a tumor niche to sustain CAFs which in turn maintain the TME. This 
notion is underscored in vivo with mice lacking S100A4 which inhibits myofibroblast 
differentiation and prevents metastasis (Grum-Schwensen, B. et al., 2005). Thus, the disruption 
of bioactive CAF signaling should hypothetically stall progression via elimination of the TME.  
1.2.4  CAFs modify ECM to reinforce tumor progression   
Cancer associated fibroblasts are the presumptive key ECM producing and remodeling cell 
population within the TME. The ECM is an ornate network of cross-linked proteins that relays 
biophysical and biochemical signals to contextually regulate tissue development, cell proliferation, 
survival, and motility (Naba A et al., 2012). Despite transient dysregulation during wound healing, 
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the persistence of aberrant ECM contributes to fibrotic disease and malignant progression. In this 
context the ECM is three-dimensional bioactive scaffold that acts as a foundation for cells, 
providing mechanical stability and physiochemical signals via sequestration of growth factors and 
cytokines (Pickup M et al., 2014). However, the ECM present in solid tumors differs dramatically 
from healthy tissue.  
Tumor ECM is rich in fibrillar collagen (COL-1) but also type III, IV and V, hyaluronan, 
fibronectins, laminins which comprise basement membranes, and wound response matricellular 
protein tenascin-C (TNC) (Ronnov-Jessen, L et al., 1996; Rodemann, HP et al., 1996; 
Tomasek, JJ et al., 2002). This complex ECM network is regularly pruned and remodeled 
primarily due to CAF proteases driving the release of cryptic growth factors such as VEGFA to 
promote angiogenesis. However, the disorganization of the ECM impacts the leakiness of vascular 
beds leading to hypoxia, a feature that is associated with adverse outcomes (Acerbi I et al, 2015; 
Gilkes D et al., 2014; Levental KR et al, 2009; Lu P et al, 2012; Naba A et al, 2014). Other 
important molecules such as TGFβ and macrophage chemotactic protein 2 (CCL2) are released 
during ECM remodeling. These molecules impact melanoma invasiveness through TGFβ driven 
EMT and recruit immune cells which are reprogrammed due to immunosuppressive CAF activity 
(Flavell, RA et al., 2010; Kim JH et al., 2012; Yang, X. et al., 2016). Thus, excessive ECM is 
pathological, yet there is only a facile understanding of how key proteins impact progression 
1.3 Tumor ECM is dynamically modified in melanoma 
As melanoma tumors expand the ECM is the first barrier to spreading. Vertically invading 
melanomas must (1) polarize the cell body, (2) utilize integrins to develop focal adhesions to the 
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ECM (3) secrete proteases and matricellular proteins at the leading edge to disrupt the basement 
membrane, and lastly (4) retract the lagging edge to transit into the dermis. There melanomas 
interact with tissue-resident fibroblasts which are converted to CAFs. In addition to ECM 
synthesis, CAFs also produce ECM modifiers (e.g. lysl oxidase, LOXL2) that crosslink ECM 
proteins thereby stiffening tumors, and MMPs which proteolytically degrade matrix to permit 
invasion (Nguyen EV et al., 2019; Tang X et al., 2016; Mohammadi H et al., 2018). For 
example, sromelysin-1 (MMP3) is released by CAFs to actively cleave cell-cell adhesion molecule 
epithelial cadherin (E-cadherin) to promote cancer EMT (Lochter, A. et al., 1997).  These 
mesenchymal cells are highly motile due to the tumor ECM, which is characterized by decreased 
cell adhesion, which is a microscale feature that favors cell motility (DiMilla PA et al, 1993).  
Interestingly, TGFβ has been experimentally linked to pro-tumorigenic CAF recruitment to 
promote tumor ECM that correlates to increased metastasis (Dumont N et al., 2013; Madsen CD 
et al., 2015; Calon A et al., 2012; Lohr M et al., 2001; Aoyagi Y et al., 2004). Here, the focus 
is on TGFβ and how expression of this molecule is impacted by tumor suppressive ECM molecule 
decorin (DCN), and tumor promoting matricellular ECM tenascin-C (TNC).  
1.3.1 Tumor inhibiting ECM  
The ECM in healthy mature tissues presents and signals to cells differently than the 
disorganized and immature pathological ECM that is often characteristic of malignancy. As the 
ECM is bioactive, this substrate is capable of regulating multiple aspects that govern the hallmarks 
of cancer which include proliferation, circumvention of growth suppression, apoptotic resistance, 
initiation of invasion, dysregulation of cellular energetics, immune escape, and chronic 
inflammation (Pickup M et al., 2014, Hanahan D et al., 2011). The term matricellular or 
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matrikine has been proposed to define ECM proteins that contain domains which can signal within 
the tissue microenvironment (Bornstein P et al., 2002). These complex proteins are often large, 
spanning multiple to hundreds of kilodaltons. Within these large spans exist cryptic sites. These 
sites are enzymatically exposed by MMPs secreted by invasive melanomas. Additionally, the 
intravasation of malignant cells produces mechanical forces via integrin contractions of the ECM 
that drive the release of adsorbed growth factors (Maquart FX et al., 1999; Davis GE et al., 
2000).  However, these sites can be tumor suppressive or promoting within the context of the tissue 
microenvironment.  
Mature ECM is predominantly comprised of organized collagens which bind and anchor 
molecules that suppress proliferation, migration and promote differentiation (Grahovac J et al., 
2014). These proteins often appear in the end phases of tissue development or in the resolution 
phase of wound healing (Wolf K et al., 2009). Failure to clear immature matrix results in tissues 
with similar dynamics to the TME, with both conditions proceeding as incomplete chronic healing. 
Thus, it is essential to understand how the ECM in tumors coevolves within the context of the 
reciprocal signals of the tumor and the stroma. Here, the focus is on decorin, a well characterized 
ECM molecule that has been tested as a therapeutic modality against multiple cancers and is shown 
here to inhibit melanoma invasion (Neill T et al., 2016). 
1.3.1.1 Decorin 
Decorin is a small leucine rich proteoglycan (SLRP) that is synthesized by stromal 
fibroblasts and smooth muscle cells. This small SLRP decorates collagen leading to readily 
accessible inhibitory interactions with growth factor receptors such as EGFR, Met, and PDGF 
(Zhang G et al., 2006; Iozzo RV et al., 1999; Goldoni S et al., 2009; Merline R et al., 2011). 
Subsequently the protein core and single chondroitin/dermatan sulfate glycosaminoglycan chain 
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attached to a serine near the N terminus, facilitates multiple binding interactions that endow DCN 
with anti-tumor capacities (Keene DR et al., 2000). There are two sites within the DCN core that 
bind and sequester TGFβ. Decorin has also been described as the “guardian from the matrix” and 
is a pan-kinase inhibitor which blunts tumor cell migration via the inhibition of growth factor 
receptors. Interestingly, DCN also leads to E-cadherin expression in opposition of tumor EMT 
(Neill et al., 2012; Hildebrand A et al., 1994; Bi X, et al., 2012; Sofeu Feugaing DD et al., 
2013). Moreover, quiescent fibroblasts produce DCN while actively proliferating fibroblasts have 
reduced DCN expression which is more in line with the production of pro-tumorigenic matrix. In 
tumors DCN is found in the peritumor stroma but is excluded within the invading tumor where 
immature matrix such as TNC is high and cells are positive for EMT (Franz M et al., 2006; 
Grahovac et al., 2013; Hlubek et al., 2007). Thus, redistributing DCN into the invading tumor 
has therapeutic potential to inhibit invasion by homeostasis of the ECM.  
1.3.2 Tumor promoting ECM molecules  
The ECM is an amendable substrate that is modified in response to the cells that dwell on 
the surface. Normal tissues tightly regulate the release of growth promoting factors that activate 
proliferation via induction of the cell-cycle to maintain homeostasis. Organize tissue architecture 
regulates cell cycle progression by promoting cellular attachment to the ECM (Pickup et al., 
2014). In contrast, malignant cells secrete modified matrix to disrupt adhesion, enabling escape 
from the proliferative control of the ECM (Zahir N et al., 2004). The acquisition of tumor-ECM 
secretion is activated by oncogenic RAS which signals via ERK to induce anchorage independence 
that is linked to altered ECM expression (Pattabiraman PP et al., 2010). During this process the 
release of growth factors and inflammatory ECM activate the quiescent stroma. This activation 
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cascade drives an exuberant expansion of cells and the formation of the TME which appears to 
stiffen in solid tumors overtime, a biomechanical feed-forward process that drives progression 
(Provenzano PP et al., 2008; Wells RG., 2008). 
In response to injury or invasion, stromal cells activate developmental ECM gene 
expression to initiate repair (reviewed by Sylakowski et al. 2020, Appendix B). These transiently 
expressed proteins decrease ECM density and adhesiveness to promote cell migration. Malignant 
cells exploit the intermediate adhesiveness of matricellular proteins, displaying decreased dwelling 
time and escape from proliferative control (DeMilla et al., 1991, 1993). Matricellular proteins, 
Tenascin-C (TNC), thrombospondin (TSP), laminins, and secreted protein-rich in cysteine 
(SPARC) are increased in sites of inflammation and in the TME (Grahovac et al., 2014). 
Additionally, TGFβ has paradoxical roles in progression wherein this molecule is tumor 
suppressive during early progression via anti-proliferative signaling. In late stage progression, 
TGFβ released from inflammatory immune cells and a reactive stroma synthesizing tumor ECM 
is reported to activate malignant EMT (Massagué, 2008; Leight J et al., 2012). Moreover, TGFβ 
is hypothesized to recruit and stimulate inflammatory cells to the invasive tumor margins. Here 
these cells secrete MMPs which facilitate malignant amoeboid invasion (Talmadge et al., 2010, 
McGowan et al., 2009, Aguirre-Ghiso, 2007; Townsen et al., 2006 and Fidler, 2003). Thus, the 
tumor promoting ECM molecules are crucial to promote invasion. Here, the role of TNC is 
emphasized as it shown to promote melanoma invasion.  
1.3.2.1 Tenascin-C  
Tenascin-C is a multi-domain glycoprotein with diverse functions in developmental 
contexts, wound healing, and malignancy (Giblin S et al., 2014). Structurally, TNC is a 
homodimer of homotrimers linked by disulfide bonds within the N-terminal trans-assembly 
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domain (TA-Domain), giving rise to a hexabrachion structure (Jones SF et al., 2000; Hancox RA 
et al. 2009).  Each TNC monomer is composed of domains including the TA, EGF-Like (EGFL), 
Fibronectin type III (FNIII) and fibrinogen globe (FBG). The FNIII domains are subject to exonic 
alternative splicing resulting in products of molecular weights between 180-330 kDa (Midwood 
KS et al., 2009). The FNIII and FBG domains are considered adhesive due to integrin binding 
(Hancox RA et al. 2009; Saito Y et al., 2007; Joshi P et al., 1989; Grahovac J et al., 2014; 
Fowler WE et al., 1979; Leahy D et al., 1992; Gulcher JR et al., 1989). Conversely the EGF-L 
domains are anti-adhesive and function as an ultra-low affinity ligand for EGFR, measured at KD 
= 74μM (Swindle CS et al., 2001; Iyer AK et al., 2007). However, TNC matrix tethering 
augments the strength of TNC-EGFR binding, driving ‘high avidity/low affinity’ restriction of 
EGFR to the cell membrane [enriched in lamellipodia] (Shao H et al., 2015). Restriction of EGFR 
in this manner shifts the balance of cell adhesion/contraction to favor migration in a mesenchymal 
state or reversion to amoeboid for 3D invasion, in place of proliferation (Grahovac J. et al. 2012; 
Zaman MH et al., 2006; Friedl P et al. 1997;  Friedl P et al., 2012; Iyer AK et al., 2008). The 
low cell adhesion to TNC has been shown to promote invasion by both MMP and protease 
independent mechanisms (Tremble P et al., 1994). In this regard TNC and the adhesion 
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modulating properties of this matricellular protein have been correlated to pro-metastatic activity 
(O’Connell, JT. et al., 2011). 
 
 
Figure 3: Tumor supportive ECM: TNC expression in normal and malignant tissue 
Tenascin (TNC) is largely absent in mature tissue (Left) where expression is tightly regulated. However, 
TNC expression is markedly upregulated at the protein level in multiple cancers including brain, bone, 
prostate, intestine, lung, skin and breast (Pas J et al., 2006).  Data are reproduced from the Human Protein 
Atlas (Uhlén M et al., 2015, 2017).  
 
Tenascin-C is largely absent in adult tissues but is paradoxically and aberrantly present in 
several cancers (Figure 2) (Tucker RP et al., 2009; Uhlén M et al., 2015, 2017; Orend G et al., 
2006). Invasive cancers, including metastatic melanoma have enrichment of TNC at the invasive 
front. This expression pattern in melanomas is linked to poor recurrence-free survival (Oskarsson 
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T et al., 2011; Lowy CM et al., 2015). Interestingly, TNC expression persists in melanomas, even 
in the absence of growth factors (Herlyn M et al. 1991). Additionally, increased expression of 
TNC is indicated during the transformation of melanocytes (Hoek K et al., 2004). TNC expression 
continues to increase during progression from benign to metastatic melanoma, indicating a 
functional importance in metastasis. However, mechanisms governing how melanomas acquire 
TNC expression are currently ill-defined, especially with regard to dynamics of expression and the 
correlate function(s).  
Our previous studies indicate that the overexpression of TNC-EGFL monomers are 
sufficient to convert a radially invasive melanoma cell to vertically invade human three-
dimensional organotypic skin organ cultures (SOC) (Grahovac J et al., 2012). Coupling these 
findings to evidence that (i) TNC can drive EMT programs in breast cancer (Nagaharu K et al., 
2011), (ii) activate CAF secretion of TNC (Chiquet-Ehrismann R et al., 1986; Mackie EJ et al., 
1987), (iii) and promote melanoma progression and resistance to doxorubicin in vitro (Fukunaga-
Kalabis M et al., 2010), identifies TNC as a suspect player in supporting melanoma.   
Thus, the tumor and stroma coordinate to develop the TME by reverting to onco-fetal 
development and wound healing programs. Presentation of ECM, matricellular proteins, and 
soluble signals in this fashion largely reprograms malignant and stromal cells to promote 
progression. Overtime, accumulation of this tumor-associated ECM results in invasion and 
resistance. However, despite experimental correlations to clinical biopsies, the specific 
mechanisms driving the evolution of tumor-ECM remain elusive. This has prompted broader 
investigations into the complete repertoire of ECM and how these molecules shift in expression to 
favor progression.   
 17 
1.4 The notion of a core matrisome 
There is considerable overlap of a large number of ‘onco-fetal-wound’ ECM reported 
during malignant progression. These molecules and matricellular proteins are often temporally 
restricted yet reappear during the establishment of the TME. This led to an effort to characterize 
the ECM to determine composition and functions in tumors. Genomics provided the key the 
elucidating specific identifiable features of ECM proteins based on distinctive structures and the 
repetition of conserved domains (Engel J et al., 1996; Hohenester E et al., 2002). The ECM 
proteins comprise a relatively small repertoire (~100 proteins) of phylogenetically conserved 
amino acid domains which have been characterized and defined in silico. This inventory of 
proteins, termed the core matrisome (CM) represents ~278 genes for ECM glycoproteins, 
proteoglycans and collagens with matrisome-associated proteins comprising ~778 genes 
representing ECM regulators, ECM-associated, and secreted factors (Naba A et al. 2012). These 
genes are differentially expressed and dictated by the contextual or pathological tissues from which 
they are extracted. The composition of the ECM proteins is reported to shift dynamically in cancer, 
where metastatic cells elicit changes distinct from low grade malignancy, again suggesting the 
tumor ECM is constructed via dynamic reciprocity of tumor-stroma signaling.  
These early studies laid the foundation for refined studies, wherein subsets of the CM or 
CM-associated proteins could be further enriched to select targets for specific malignancies. 
Despite correlative evidence that excessive deposition of ECM is linked to poor prognosis, only 
incremental advances have been made towards understanding which specific proteins contribute 
mortality.  
Recently, bioinformatics has helped bridge this gap, enabling high level analyses of ECM 
signatures that are most common between multiple cancer types. These gene-signatures can then 
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tested against clinical samples to develop a predicative core matrisome (Yuhzalin AE et al., 2018).  
The outcome of this study is a nine-gene ECM signature among solid adenocarcinomas that was 
shown to have predictive value. This signature contains collagens (e.g. COL1A1) as well as 
secreted molecules which bind ECM (e.g. osteopontin, SPP1). These signatures were also linked 
to EMT, hypoxia, angiogenesis and inflammation by gene set enrichment analysis thus, providing 
a biological basis for defining hitherto disparate ECM molecules. A similar approach discovered 
that cancers with mutations in BRAF, SMAD4 (TGFβ pathway), TP53 and amplifications in MYC 
activated a TGFβ response in CAFs to produce cancer-ECM and resistance to programmed death-
1 (PD1) check point inhibition (Chakravarthy A et al., 2018). The high-grade expression of 
TGFβ in CAFs was predicted to correlate with immune exhaustion and PD1 blockade in patient 
melanoma samples using the dataset from Tirosh et al., 2016. The study was able to conclude that 
high predicative scores in CAFs positive for cancer-ECM expression in addition to TGFβ1/ TGFβ2 
expression, was indeed powerful enough to predict PD1 blockade (p<0.007). Thus, targeting the 
TGFβ signaling axis may prove therapeutically beneficial in the effort to normalize tumor ECM. 
This notion is underscored by evidence that despite being ‘immunologically hot,’ tumors 
expressing a negatively prognostic ECM signature correlated with the eventual loss of checkpoint 
inhibition prior to clinical manifestation.  
Despite the potential insights offered from defining a core cancer matrisome, these in silico 
approaches do have limitations. For example, these gene signatures are often based on subsets of 
disease types or small patient populations. The analyses are also computationally derived and 
based on post-hoc analysis of clinically treated and documented patients. Therefore, there is 
currently a lack in our understanding for how these molecules interplay upstream of the clinical 
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manifestation of disease. Here, the gap regarding the mechanistic processes that underly therapy 
failure and how cancers co-opt the TME to promote invasion and metastasis remains unbridged.   
1.5 Hypothesis and major findings 
Given the strong association between secreted signals and pathological ECM, this study 
was developed to (I) elucidate the mechanism by which TGFβ drives the phenotypic conversion 
of CAFs, including how the stroma modifies microenvironmental ECM, and (II) Therapeutic 
strategies to target the TGFβ signaling axis to prevent melanoma metastasis by limiting the 
inflammation and development of a pro-tumorigenic ECM. This thesis shows that the inflamed 
TME is characterized by the expression of immature ECM proteins and inflammation. We 
elucidate that the pathological matrisome produced by αSMA+ CAFs promotes melanoma invasion 
and proliferation. Transforming growth factor-β receptor (TGFβR) promotes CAF expansion in 
response to the secretome of therapy-stressed melanoma. Blockade of TGFβR suppresses CAF 
inflammation and normalizes the ECM to halt melanoma progression and proliferation. Combined 




2.0 Materials and Methods 
2.1 Cell culture  
WM983A, WM983B, WM1158 were purchased from the Wistar Collection at Coriell Cell 
Repository. Cells were cultured in a mixture of DMEM (Cellgro, 10-014-CV) and Leibovitz L15 
(Gibco, 11-415-064) at a ratio of 3 to 1 and supplemented with 5% (v/v) fetal bovine serum (FBS, 
Gemini Bio, 100-500) and 100 units per milliliter penicillin and streptomycin (Gibco, 15-140-48). 
A375 melanoma cells were from Dr. John Kirkwood (UPCI), originally obtained from ATCC and 
cultured in DMEM (Cellgro, 10-013-CV) supplemented with 10% FBS and 100 units per milliliter 
penicillin and streptomycin. Primary melanoma patient cell line TPF-12-293 melanoma cells were 
from Dr. John Kirkwood (UPCI) and cultured in RPMI 1640 (Gibco, 11875119) supplemented 
with 10% (v/v) FBS, 1% Non-essential amino acid (NEAA, Gibco, 11140076), 1% HEPES 
(Gibco, 15630130) and 100 units per milliliter penicillin and streptomycin. Fibroblasts HS68, TP-
1170, and melanoma derived CAFs TP-50236 and TP-50306 (tumor adjacent and tumor distant) 
were cultured in DMEM (Cellgro, 10-013-CV) 10% (v/v) FBS and 100 units per milliliter 
penicillin and streptomycin. Cell lines were cultured at 37°C in 5% CO2 and the medium was 
replaced as required.  
 21 
2.2 Generation of Therapy Resistant Cell Lines  
Vemurafenib and PD153035 resistant melanoma cell lines were developed according the 
method of Obenauf et al. 2015. Human melanomas A375, WM983B and WM1158 were seeded 
at low density in 5cm tissue cultured treated dishes for 24 hours in normal growth medium. The 
media was then replaced with either DMEM 5% FBS or normal growth medias supplemented with 
PD153035 (Selleck Chemicals, S1079) or Vemurafenib (Selleck Chemicals, S1276), respectively. 
Therapy sensitive cells were exposed to 5μM PD153035 and 1μM for W983B and 3μM 
Vemurafenib for A375 and WM1158. After 8 weeks of treatment resistant clones (R) of A375R, 
WM983BR and WM1158R were analyzed for dose-dependent responses to inhibitors and receptor 
status was analyzed by western blot. Increased expression for EGFR and levels of phospo-ERK 
and phospo-AKT were compared to the therapy sensitive parental cells (Figure 19B).  
2.3 Patients and Biospecimens  
All experiments using patient tumors were consented and approved by the Allegheny 
Health Network and are exempt by the University of Pittsburgh IRB. Tumors from melanoma 
patients were surgically excised and washed in DMEM (Cellgro, 10-013-CV) containing 2(x) 
antibiotic/antimycotic solution (Sigma, A5955). Tissues were then washed in Hanks balanced salt 
solution (HBSS, Gibco) containing 1% antibiotic/antimycotic (A/A). Tumors were transferred to 
a 10cm dish mechanically minced using sterile razor blades to less than 1 sq. mm and incubated 
win 70units/ml collagenase (Worthington, M2N5857) and 50units/mL Dispase (Gibco, 17105-
041) dissolved in serum free DMEM (10-013-CV). Tissues were incubated for 1hr in the 
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dissociation media at 37°C in 5% CO2. Next, tissues were mechanically separated using the 
plunger from a 10ml sterile syringe and incubated for an additional hour at 37°C in 5% CO2. The 
enzymatic dissociation media was quenched with normal growth medium containing 20%FBS. 
The cell solution was strained through a 40μm mesh filter (BD Biosciences) into a 50ml falcon 
tube. Cells were spun at 1000 r.p.m for 5 minutes, aspirated and resuspended in primary melanoma 
media (RPMI 1640 (Gibco, 11875119) supplemented with 10% (v/v) FBS, 1% Non-essential 
amino acid (NEAA, Gibco, 11140076), 1% HEPES (Gibco, 15630130) and 1% penicillin and 
streptomycin). Cells were allowed to grow for 5 days after which colonies of melanoma were 
selected and expanded in 12-well plates. Patient matched fibroblasts were also collected and 
cultured separately in DMEM (Cellgro, 10-013-CV) 10% (v/v) FBS and 1% penicillin and 
streptomycin. Melanomas were positively identified by gp100 (Abcam, ab137078) or MiTF 
(ab3201). Fibroblasts were confirmed by morphology and the presence of αSMA (Sigma, A2547 
Clone 1A4). 
2.4 Cell Cocultures  
Cocultures were established by plating fibroblasts in 6 and 12-well plates at 10,500 cells 
per sq. cm and allowed to adhere overnight in normal growth media. The following day drug 
sensitive A375 or vemurafenib resistant A375R cells were seeded into 0.4μm transwell inserts 
(Falcon, 353090, or 353180) in normal growth media and allowed to adhere overnight. Media was 
then replaced with low serum (2% FBS) media containing vehicle. 1μM vemurafenib, selumetinib 
(Selleck Chemicals, S1008), or PD153035, with media for control wells plated at the same time. 
For experiments with TGFβR antagonists, 1μM vactosertib (Selleck Chemicals, S7530) or 10μM 
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SB431542 (Selleck Chemicals, S1067) and 1μM infigratinib (Fibroblast growth factor receptor, 
FGFR, Selleck Chemicals, S2183) diluted in low serum, were added to fibroblasts prior to 
melanoma seeding.  After 72hr, conditioned media was harvested, plates were washed with cold 
PBS (Cellgro, 21-040-CV). Cells were then prepared for analysis of RNA, protein or 
immunofluorescence. Coculture experiments were independently performed three times and a 
representative experiment is shown. 
2.5 Conditioned Media Protocol 
To generate conditioned media, 1x106 drug sensitive melanoma cells were plated in 10cm 
dishes in DMEM (Cellgro, 10-013-CV) supplemented with 10% FBS and 1% penicillin and 
streptomycin and allowed to adhere overnight. The media was then replaced with low serum (2% 
FBS) media containing vehicle, 1μM vemurafenib, 0.1μM selumetinib and 5μM PD153035 (1μM 
for WM983B) with control wells plated at the same time. After 72hr cells were approximately 
~90% confluent and media was collected, centrifuged at 1,500 r.p.m. for 5 minutes, filtered and 
aliquots were stored at -80°C. Media was used for key coculture experiments.   
2.6 Quantitative PCR 
Whole RNA was isolated from treated melanoma cells using the RNAeasy Mini Kit 
(Qiagen) according to manufacturer specifications. RNA from coculture experiments was isolated 
using Trizol (Ambion) separately from fibroblasts and melanomas after transwells were put into a 
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fresh 6-well plate RNA was reconstituted in nuclease-free water and concentration was measured 
by Nanodrop. Samples were stored at -80°C prior to reverse transcription to derive cDNA using 
the QuantiTect reverse transcription kit (Qiagen, 205313). Samples were stored at -20°C. 
Quantitative PCR was performed using RT2 SYBR Green Master mix (Qiagen) in 96 well plates 
on a Stratagene Mx3000P. Quantification was calculated using the ΔΔCt method with GAPDH as 
the control. All data points represent at least 3 technical replicates and experiments were 
independently performed twice. A representative is shown.  
2.7 Immunoblotting  
Cells were rinsed in PBS and lysed using ice cold RIPA buffer containing protease inhibitor 
cocktail (Calbiochem, 535140) and phosphatase inhibitor cocktail (Sigma, P5726) according to 
manufacturer specifications. For the analysis of matrikines or extracellular matrix proteins, cells 
were washed with PBS and lysed directly into laemelli buffer containing 10% β-mercaptoethanol. 
At this point all samples were sonicated on ice. Samples were then placed at 4°C for 20 minutes 
and then centrifuged at 15,000 r.p.m. for 30 minutes.  Protein concentrations of RIPA samples 
were determined using a BCA Protein Assay Kit (Pierce). In most cases samples were collected 
using both buffers and concentrations were assumed to be similar based on protein weight. Proteins 
were separated by SDS-PAGE using bis-tris 7.5% polyacrylamide gels in tris-buffered saline and 
transferred to PVDF membranes using a Bio-Rad transfer system according to standard protocols. 
Membranes were blotted with primary antibodies diluted in 5% bovine serum albumin in tris 
buffered saline 0.1% Tween 20 and 0.02% sodium azide (TBST) for Tenascin C (ab108930), MiTF 
(ab3201) from Abcam, E-cadherin (3195), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
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(4370), Pan AKT (4685), GAPDH (5174), tEKR (p44/42 MAPK (Erk1/2)) (9102), α-Tubulin 
(2144) from Cell signaling, and αSMA (A5228) from Sigma Aldrich. All primary incubations were 
on a low speed shaker overnight at 4°C. Membranes were incubated with secondary antibodies 
from Sigma Aldrich 12-348 (Rabbit) and 12-349 (Mouse) diluted in 5% non-fat dried milk diluted 
in TBST for 2hr. All antibodies are described in the Supplementary Information. Membranes were 
washed three times with TBS in between antibody incubations and detected using 
chemiluminescence according to standard procedures. Radiographs were processed and scanned. 
2.8 Immunofluorescence and Imaging 
Cells were seeded onto glass coverslips at 5x105 per well in 12-well plates in normal 
growth media and incubated overnight. After coculture or drug treatment cells were washed in 
PBS and fixed in 4% paraformaldehyde. Cells were lysed using 0.1% Triton-X 100 (Fisher 
Scientific) for 15 minutes on a rocker at medium speed. Samples were then blocked for 1hr using 
5% BSA diluted in PBS. Samples were then washed and incubated with primary antibodies in 3% 
BSA /PBS overnight at 4°C. Cells were washed with PBS and incubated in 1% BSA/PBS with the 
species appropriate secondary antibody (Supplemental Information). For F actin staining, 
100ng/mL AlexaFluorTM 594 or 488-AlexaFluorTM phalloidin (Thermo Fisher) was diluted in 1% 
BSA/PBS with secondary antibodies and incubated for 1hr. Samples were then washed in PBS 
and incubated in 6.6μM Hoechst 33342 (Thermo Fisher) in 1% BSA/PBS, washed in PBS, and 
mounted in Prolong gold antifade reagent (Invitrogen). Epifluorescence was performed on 
Olympus X71 microscope equipped with a Spot InsightTM CCD digital camera (Spot Imaging 
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Solutions) using 10, 20 and 40x/0.6na objective (Olympus). Image analysis was performed in post 
using ImageJ (https://imagej.nih.gov/ij/) or NIS Elements Advanced Research software.  
2.9 Immunohistochemistry 
Patient samples were collected under standard clinical management with approval of the 
UPMC institutional review board for protocol(s) 1611. Tumor samples from the Allegheny Health 
Network were considered exempt. Patient-informed consent was obtained for the research 
performed in this study. Human melanoma microarrays ME1004a, ME1004g, and ME1004h were 
purchased from Biomax. Xenograft tumors were collected from euthanized animals in fresh 10% 
neutral buffered formalin and paraffin embedded (FFPE) through a series of dehydration steps at 
the University of Pittsburgh Biospecimen Core. Tumors were then sectioned using a sliding 
microtome (Fisher).  Tumor slices (5μm) and tissue arrays were de-paraffinized by baking for 1hr 
at 55°C, then immediately placed into Xylene (Fisher) baths (3 each), transferred to 100%, 95% 
and 80% ethanol. Following, this samples were washed in PBS five times and placed into citrate 
buffer at 95°C for 10 minutes and cooled to RT for 1.5hr. Samples were then washed in PBS and 
quenched with 3% hydrogen peroxide. After PBS washing, samples were blocked in 20% goat 
serum for 1hr, and primary antibodies were diluted in blocking buffer for overnight incubations at 
4°C. Samples were stained with of αSMA (Sigma, A2547 Clone 1A4), Tenascin (BC-24, Santa 
Cruz Bio.), Decorin (R&D), and Collagen I (Abcam). Samples were then washed with PBS and 
incubated in species appropriate secondary antibodies. All antibodies are detailed in the 
Supplementary Information. After incubation, samples were treated with ABC reagent (Vector 
laboratories, PK-6100) for 30 minutes, washed in PBS and developed with DAB reagent kit 
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(Vector laboratories, SK-4100), counterstained with H&E, clarified (Richard Alan Scientific) and 
dehydrated in ethanol and xylene. Samples were mounted (Fisher Scientific, SP15-500) and 
imaged on an Olympus BX40 upright microscope equipped with a Spot FlexTM CCD digital 
camera (Spot Imaging Solutions) using 4x, 10, 20x and 40x (UPlan) objectives (Olympus). Image 
analysis was performed using ImageJ. 
2.10 Lentiviral Infection  
All constructs are described the supplementary information. Fluorescent reporters for GFP 
and RFP were purchased from Origene and added to normal cell growth medium containing 
polybrene (6μg/mL). A total of 5-10μL or viral particles was added to individual 96 wells 
containing melanoma cells lines that were plated the day before at 2000 cells per well. 
Transduction and fluorescence were confirmed after 36 hours and cells were split to 12-well plates 
for expansion. Clones were selected using puromycin and blasticidin, respectively. Fluorescence 
clones were expanded in normal growth media containing antibiotic and further purified by FACS 
at the University of Pittsburgh Flow Cytometry Core and were used for spheroid studies.  
2.11 Three-dimensional Spheroid Assay 
The method of Kaur et al. was followed for the development of assays (Supplementary 
Ref. 3). Briefly, sterile 96 well plates were coated with 50μL of 1.5% agarose (Sigma, A9539) 
dissolved in DMEM (10-013-CV) that was heated to a boil. Melanoma cells were then plated at 
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1x104 cells diluted in normal growth media at 50μl per well. After 72 hours cells formed dense 
tissue spheroids. For spheroids and fibroblast cocultures, 4x103 fibroblasts were seeded into 8μm 
falcon permeable supports – transwells, (Falcon, 353097) into 24-well plates and adhered 
overnight. Otherwise, melanoma spheroids were harvested using a p200 micropipette and 
deposited into 50μL of 2 or 4mg/mL rat tail collagen type I (Corning, 345249) dissolved in 50mM 
HEPES pH 8. Normal growth media with or without inhibitors was added to the upper and lower 
chamber of the transwell. Quantitation of invasive outgrowth was performed using ImageJ 
software. 
2.12 Thick collagen invasion assays  
Acellular collagen I matrices were prepared using rat tail collagen type I (Corning, 345249) 
at 3mg/mL and casted into 8μm transwells (Falcon, 353097) 50μl per insert. For studies involving 
matrix proteins, 4μg/ml of tenascin-C (Millipore, CC065) or decorin (R&D Systems, 143-DE-100) 
were added prior to gel neutralization.  Matrices were placed into 37°C in 5% CO2 to polymerize. 
Melanoma cells were seeded into the scaffolds at 5x104 in low FBS media and with normal growth 
media in the lower chamber. Gels were fixed after 72hr and stained as described with a 
modification for phalloidin (Hopper et al., 2006). Briefly, collagen inserts were washed with PBS, 
fixed for 30 minutes in 4% formaldehyde-0.25% glutaraldehyde in PBS, treated with 0.1% Triton 
X for 30 min on ice, and stained with 0.2μg/ml 488- AlexaFluorTM phalloidin (Molecular Probes, 
Invitrogen) and 2μg/ml DAPI (Sigma) in dark for 3h. Gels were imaged directly in the inserts in 
PBS on the Nikon Swept field Confocal Microscope (TSI inverted) using 10X and 60X 1.4 NA 
objectives. 3D volume representations of Z-stacks were made using Nikon Elements Advanced 
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Research software and surfaces of the invading cells were modeled with Imaris software based on 
the absolute intensity of phalloidin staining with 3μm surface area detail level (Bitplane, Zurich, 
Switzerland). Quantification of the depth of invasion was performed with the length measurement 
tool of Nikon Elements Advanced Research software by measuring 60 random positions per 
sample from the surface of seeded cells to the bottom most detected intensity. Experiments were 
repeated three times. 
2.13 Organotypic three-dimensional skin reconstructs 
Skin organ cultures were established as previously described (Grahovac et al., 2012; 
Simpson et al., 2010), with modifications. Briefly, 15x104 primary human fibroblasts were seeded 
in 1.5 ml 2mg/ml collagen gels alone or with the addition of 4μg/ml of TNC, DCN or both, in 24 
well plates. After 5 days in submerged culture, 25x104 normal human keratinocytes were seeded 
on top of contracted gels. Keratinocytes were allowed to adhere and 48h later 10x104 WM1158 
cells were seeded in the center of the plug within the 4,7mm R cloning rings (Bel Art, 14-512-78, 
Thermo Fisher Scientific, Pittsburgh, PA), let attach for 8h and then the cloning rings were 
removed. After 3 days, the cultures were lifted to the air liquid interface to allow epidermis 
maturation and the medium was replenished every other day for total of 20 days of culture. The 
samples were fixed and paraffin embedded and H&E stained as previously described (Hood et al., 
2010). The experiment was repeated two times with similar results. 
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2.14 Animal Studies  
All animal studies and procedures were approved and performed at the AAALC-accredited 
IACUC of the Veteran’s Administration Pittsburgh Health System. Adult (5-6-week-old) NOD-
scid IL2Rgnull (05557, Jackson Laboratory) female mice were anesthetized with ketamine/xylazine 
and buprenorphine to relieve pain. Spleens were exposed by left lateral incision in a sterile tissue 
culture hood wherein 5 x105 human A375 or patient metastatic 12-293 melanomas, and 2.5 x105 
metastatic WM1158 cells were injected at 50μL per animal using a 26.5-gauge needle. Incisions 
were closed using 5-0 vicryl suture and two staples. Animals were warmed and monitored until 
recovery and housed individually. Tumors were allowed to grow untreated for 4 weeks be 
euthanasia. For therapeutic studies, animals bearing 12-293 tumors were injected on Day 7 with 
vehicle (10% DMSO in FBS) or MEK inhibitor (AZD6244, 10mg/kg) or a combination of 
AZD6244 and vactosertib (5mg/kg) prepared fresh in warmed FBS. On day 30 animals were 
euthanized to collect spleen, liver and lungs for micro-or-macrometastatic analysis. 
Patient derived xenograft (PDX) studies were conducted using patient biopsies received 
from the Allegheny Health Network and were approved by both institutions. Fresh excess tissues 
were surgically removed from patients with treatment refractory melanomas and saved for 
pathology and analysis, while small 10mm3 pieces were washed in DMEM (10-013-CV) with 2x 
(A/A) and stored in cold HBSS with 1x (A/A). Five-week-old NOD-scid IL2Rgnull were 
anesthetized and treated as treated as previously described. A small pocket in the left flank was 
formed for subdermal placement of tumors. The incisions were sutured, stapled, and animals were 
warmed and allowed to recover before individual housing. PDX tumors were grown in P0 mice 
for approximately 3-6 months as determined by tumor size (~100mm3) using the formula, tumor 
volume = (D x d)2/2 in which D and d represent x and y tumor diameter. These tumors were split 
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into ~50mm3 sections for analysis and cell culture, and passage to a P1 NOD-scid IL2Rgnull mouse. 
Animals in the P1 cohort were euthanized after ~6 months and tumor, liver, spleen and lung were 
harvested for analysis. De-identified information of tumors is described in the Supplementary 
Information. 
2.15 Statistical Analysis 
 Data are presented as the mean  s.e.m., for three independent experiments. Significance 
between comparisons with two independent variables was determined by a Student’s two-tailed 
unequal variance t-test. One-way ANOVA was used to compare significance for more than 2 
variables and between biological replicates. Significance levels and the tests used to determine 
these values are reported in the figure legends. Significance is represented in all figures with 
symbols denoting *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 
 32 
3.0 The Therapeutically Inflamed TME Drives Melanoma Progression 
3.1 Introduction 
Therapeutic regression of the tumor microenvironment (TME) is often hampered by drug 
resistance (Holohan C et al., 2013). This inevitable feature is common in solid tumors which 
contain diverse tumor and cancer-supportive stromal populations. Together, these cells secrete 
heterotypic signals to sustain tumor proliferation, invasion, and drive treatment attenuation 
(Straussman R et al., 2012; Junttila MR et al., 2013; Egebald M et al., 2010). Treatment failure 
is complex and linked to multiple paradigms that evolve with the TME. For example, prolonged 
exposure to inhibitors of BRAFV600E, a mutation present in ~35-50% of melanomas, drives the 
formation of resistant clones which are supported by a drug-sensitive cell secretome (Cancer 
Genome Atlas Network., 2015; Villanueva J et al., 2010). This therapy-induced secretome is 
reported to promote tumor progression in melanoma and is associated with the loss of disease 
stabilization within 6-12 months (Obenauf et al., 2015; Shi H et al., 2014). Dual inhibition of 
RAF and PI(3)K/AKT/mTOR was found to be effective in treating BRAFV600E resistant 
melanomas, however combined therapy preceding checkpoint inhibition failed to prevent 
emergence of metastatic disease due to MAP2K activation (Richmond CS et al., 2019). Single 
cell profiling of tumors from melanoma patients has revealed complex cellular ecosystems wherein 
a high density of cancer-associated fibroblast (CAFs) are associated with melanomas expressing a 
genetic signature for BRAF/MEK resistance. These same CAFs lose the expression of a unique 
set of immune modulating genes upon removal from the TME implying that these phenotypes are 
context dependent (Tirosh et al., 2016).  
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The TME is a site of persistent inflammation due to the reactive stroma, which is associated 
with angiotropism in melanoma (Bald T et al., 2014). Among the infiltrating immune cells, CAFs 
are pro-angiogenic, pro-inflammatory, produce immune suppressive cytokines, and aberrantly 
deposit extracellular matrix (ECM) (Kim DJ et al., 2018; Quail DF et al., 2013). CAFs lack a 
clear molecular distinction in comparison to their normal counterparts but differ in the expression 
of α-smooth muscle actin (αSMA), S100A4 and type 1 collagen (COL-1) (Kullari R., 2016; 
Sugimoto H et al., 2006). In melanoma, the production of ECM proteins is significantly altered 
compared to normal skin; components characteristic of an immature inflamed dermis such as 
tenascin-C (TNC), fibronectin and secreted protein acidic and cysteine rich (SPARC) are 
upregulated, while mature matrix components such as decorin (DCN) and certain collagens are 
down-regulated (Ilomen S et al., 2004; Pickup M et al., 2014; Kunigal S et al., 2006; Hood BL 
et al., 2010). We have previously reported that invading melanomas secrete TNC at the invasive 
front (Grahovac J et al., 2013). Separately, invasive breast micrometastases expressing TNC 
displayed enhanced survival and colonization (Oskarsson et al., 2011). Taken together, changes 
in ECM and links to poor prognosis in melanoma illuminate the matrix as a vital component for 
progression. However, large inflamed tumors are typically necrotic and inactive in comparison to 
the invasive front and adjacent inflamed stroma.  
Prompted by this, we examined the therapy induced secretome to uncover signals that 
promote CAFs to produce aberrant ECM. Transcriptional profiling of drug-stressed melanoma 
revealed increases in pro-inflammatory cytokines including transforming growth factor-β (TGFβ). 
The presence of TGFβ in cell culture resulted in the expression of pathological ECM in CAFs. 
Invasive melanomas were more aggressive in coculture with CAFs which was blunted by 
inhibition of MEK. However, MEK inhibition in cocultures was associated with αSMA+ CAF 
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inflammation. Here, we demonstrate that inhibition of TGFβ receptor I (TGFβRI/ALK4/5) 
diminishes αSMA+ CAFs and limits metastasis of melanoma in vivo by preventing the induction 
of a therapy inflamed matrisome.  
3.2 Results 
3.2.1 Tumor microenvironmental matrix is altered during invasion and progression  
Invasive melanomas have been reported to occur within an altered dermal environment 
with features reminiscent of tissue injury or chronic inflammation (Bald T et al., 2014; Midwood 
KS et al., 2009). In these settings, re-expression of TNC provides for both the survival and 
migration of adherent cells while signaling suppressive small leucine rich proteoglycans (SLRP) 
are downregulated. Based on our report that inflammatory ECM is redistributed in three-
dimensional organotypic skin during melanoma progression, selected ECM protein expression was 
analyzed in human melanoma tumors (Hood BL et al., 2010). Tenascin-C was largely absent in 
benign nevi which is expected given that expression is typically limited to sites of wound repair 
and is otherwise absent in adult tissues (Shao H et al., 2015). Conversely, SLRP decorin (DCN) 
exhibits mutually exclusive patterns of high expression where TNC is absent (Figure 4A). 
Interestingly, DCN decreases in expression (p = 0.0001, benign nevi vs. lymph node and stage II 
primary tumors), while TNC increases as melanomas become more metastatic (p = 0.05, benign 
nevi vs. all conditions) (Figure 4B).  The increase is expected as given that TNC promotes 
invasion. In fact, TNC increases in vitro with metastatic cells producing the highest amounts 
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(Figure 5A). Melanomas also increase epidermal growth factor receptor (EGFR) and lose 
epithelial E-cadherin (ECAD) and microphthalmia-associated transcription factor (MITF) as they  
 
 
Figure 4: The expression of ECM shifts to promote melanoma progression 
(A) Human melanomas drive the remodeling of the extracellular matrix through increased expression of 
pro-inflammatory tenascin-C (TNC) and progressive reduction of decorin (DCN). (B) Quantification of 
total TNC and DCN expression human melanoma tissue biopsies. Data are presented at means ± s.e.m.; 





Figure 5: Melanoma phenotype shifts to promote invasion 
(A) Western analysis of matrix bound tenascin-C (TNC) from representative melanoma cell lines. (B) 
Analysis of epithelial to mesenchymal (EMT) markers correspond to melanoma phenotype with expression 
of E-Cadherin and MITF (markers of primary melanomas) and EGFR and TNC expression (markers of 
metastatic melanomas).  
 
become more mesenchymal and motile during EMT (Figure 5B). Malignant melanomas gain 
expression of AXL kinase which associated with BRAF/MEK resistance and tumor supportive 
CAF recruitment (Tirsoh et al., 2016). However, we were unable to detect an in vitro increase in 
AXL in metastatic cells (data not shown).  
Based on reports that CAFs play essential roles in promoting melanoma outgrowth by 
limiting drug penetration due to excessive deposition of fibrotic ECM, we assessed whether the 
tumor stroma was activated in human tissue microarrays (Lu P et al., 2012; Kim DJ et al., 2018). 
We observed an increase in total αSMA+ which tracked with malignant severity and appears more 
organized as stress fibers at high-grade, indicative of myofibroblasts (Figure 6A). Increased 
αSMA+ correlates with a reported increase in CAFs in high-grade serous ovarian cancer (Pearce 
OMT et al., 2018). Collagen type-1 expression was more ubiquitous with respect to the grade of 
melanoma but tracks with the expression of TNC and αSMA. Thus, increases in fibrotic ECM 
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correlate with high-grade malignancies that are hallmarked by TNC melanoma invasion (Figure 
6B). Prompted by the trends from the human tissue microarray, we sought to determine how TNC 
is distributed in vivo with respect to inflamed stroma as TNC has been shown to activate pro-
inflammatory tissue destruction in arthritic disease (Rhumann et al., 2012; Bhattacharyya S et 
al., 2016). 
 
Figure 6: The tumor microenvironment becomes inflamed and fibrotic 
 As melanoma progresses from benign nevi to stage II the skin dermis increases expression of α-smooth 
muscle actin (SMA) (B) which corresponds to increases in collagen-1 (COL-1) as tumors become 
inflammatory and fibrotic. 
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To model the progression of invading melanomas in vivo, we performed intrasplenic 
injections of human melanoma cell lines A375 and WM1158, and 12-293 – a patient derived line 
from a vemurafenib treated brain mass (Figure 7A). After splenic tumors were established,  
 
Figure 7: Melanoma progression is promoted by the tumor and the stroma 
(A) Schematic and timeline of human xenograft tumor model; spontaneous metastasis from spleen to liver. 
(B) Immunostaining of mouse metastatic liver site for co-expression of αSMA and Tenascin-C. A total of 
2 or 3 animals were used for each cell line. A representative image is shown for each condition. Original 
magnification is labeled in the upper right corner.   
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animals were monitored and analyzed at 4 weeks. Analysis of metastatic liver nodules revealed 
co-expression of TNC within the invasive borders and αSMA adjacent to tumor lesions. The 
amount of TNC and αSMA corresponded to the metastatic potential of the cell line. Thus, A375 
tumors show minimal TNC expression in comparison to metastatic 12-293 and WM1158. The 
metastatic lines also have more peri-tumor αSMA expression whereas A375 nodules appear higher 
in αSMA than the surrounding tissue at the macroscopic level (Figure 7B). Conversely, despite 
total tumor burden and organ involvment in the spleens of these animals, the distribution of  αSMA 
is less clear for each of the three cell lines (Figure 8). 
 
 
Figure 8: ECM remodeling in the primary site 
Immunostaining of mouse spleen injection site does not show the coordinated expression of αSMA that is 
associated with micrometastatic outgrowth. A total of 2 or 3 animals were used for each cell line. A 
representative image is shown for each condition. 
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Figure 9: Patient progression is promoted by the tumor and the stroma 
(A) Schematic and timeline of patient derived xenograft tumor model (B) Immunostaining of human 
melanoma (SUB-Q) and mouse metastatic sites (Spleen and Liver) for expression of αSMA and Tenascin-
C. A total of 2 or 3 animals were used for each tumor. A representative experiment and image are shown 
for each condition.  
 
As the spleen is not a true representation of the ‘primary’ site for melanoma, we asked 
whether TNC and αSMA expression are microenvironmentally regulated based on tumor location.  
Thus, human patient derived xenograft (PDX) melanoma tumors were used to examine 
microenvironmental impact on ECM expression. A treatment refractory programmed death (PD1) 
treated tumor was implanted into the subcutaneous left flank of a NOD-SCID mouse.  
Subcutaneous tumors were removed after reaching 100mm3 and passaged to P1 animals where 
 41 
outgrowth was evaluated for 3-6 months (Figure 9A, above). The PDX subcutaneous tumor is 
positive for αSMA while TNC expression was undetected, in keeping with findings from early 
stage human melanomas. Metastasis to the spleen shows evidence of architectural remodeling 
marked by the presence of αSMA and with minimal amounts of TNC, similar to the A375 tumor 
of the spleen (Figure 7B). However, the architecture of the metastatic liver site shows clear 
evidence of the mutually exclusive pattern of melanoma TNC and αSMA+ CAFs. The αSMA+ 
CAFs colocalize with intratumoral TNC at the invasive front of the nodule. In addition to this, 
αSMA+ CAFs appear striatal around the peri-tumor tissue with fibrillar αSMA; these structures are 
composed of actin stress fibers at the microscale. Expression of actin stress fibers are a hallmark 
of myofibroblasts.  
Thus, despite tumor subtype or ontogeny (cell lines vs. PDX), the mechanisms governing 
architectural remodeling of ECM appears distinct to the local tumor microenvironment. Given that 
both melanomas and CAFs increase expression of secreted TNC in vitro over time (Figure 10A-
B), we sought to determine (i) what pro-inflammatory signals were upregulated in melanoma (ii) 
whether inflamed melanomas can activate CAF transformation in vitro. 
3.2.2  Therapy stressed melanomas inflame the stroma 
The tumor microenvironment is a complex niche that is replete with multiple cytokines 
such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), macrophage 
chemotactic protein-1 (MCP1/CCL2), and TGFβ, all of which are known activators of CAFs 
(Quail DF et al., 2013; Kullari R., 2016). Based on this, we queried an RNAseq dataset by (GEO 
accession GSE64671) to ascertain how cytokine expression shifts during therapy-induced stress 
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of melanomas (Obenauf et al., 2015). From this dataset, we detected increased expression of 
MCP1 (33.57-fold), multiple TGFβ ligands (TGFβ2, 7.66-fold), TGFβ receptors and latent TGFβ  
 
 
Figure 10:  Melanomas and CAFs secrete inflammatory matrix protein TNC 
(A) Melanomas increase TNC secretion correlating to metastatic potential where invasive WM983B 
BRAFV600E show marked induction compared to non-transformed WM983A. Highly metastatic WM1158 
secrete the most TNC, while malignant A375 show steady levels. (B) The pathological expression of TNC 
increases with metastatic potential and is maintained in CAFs (Aged – 50236 and Young 50306 Adjacent 
(A) and Distant (D)) relative to normal human foreskin fibroblasts (TP1170) when comparing the total 
amount of loaded protein. Samples were directly lysed in laemelli buffer.  
 
transcripts (Figure 11A).  Jun proto-oncogene (JUN) was induced 7.85-fold at 48hr treatment. 
Internal and external stimuli trigger c-(JUN) N-terminal kinase (JNK)/ stress-activated protein 
kinase (SAPK) which include growth factors, cytokines, stress-inducing signals from pathogens, 
and drugs (Wagner EF et al., 2009; Hotamisligil GS et al., 2016). Upon activation, c-JUN forms 
homo-or-heterodimers with members of proto-oncogene (FOS) and (MAF) families which form 
transcription activator protein (AP1) (Eferl R et al., 2003). Osteopontin (SPP1) was also induced 
while the leucine zipper protein FOSL1 (FRA-1) was suppressed by vemurafenib stress, in keeping 
with the report (Obenauf et al., 2015). Interestingly, 48hr vemurafenib treatment induced pro-
epithelial ECAD and MITF, while AXL and DCN induction were static. However, TNC was 
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induced nearly 3.87-fold by BRAF inhibition. Prompted by this complex transcriptional network, 
ingenuity pathway analysis (IPA) was then employed to analyze this enriched gene set by Z-score.   
Pathways showed downregulation of cell proliferation and increases in scores for cytostasis, innate 
recruitment, and organ inflammation (Figure 11B). 
The in vitro drug-stress assay was utilized to independently confirm the transcriptional 
effects of drug-induced cell stress that were obtained from the published dataset (Figure 12A). 
Inhibition of BRAFV600E (vemurafenib, IC50 ~30nM) led to an increase in CCL2, TGFβ2 and 
TGFβR2 in keeping with the dataset (Figure 11A). We expanded this analysis by targeting the 
EGFR pathway and observed EGFR inhibition (PD153035) leads to the transcriptional activation 
of these genes while downstream inhibition of MEK1/2 (selumetinib, (IC50 ~10nM) appears to 
bypass TGFβ and MCP1 gene expression despite a 10-fold lower dose. This inhibitory MEK1/2 
effect is maintained in cell culture where selumetinib induces a phenotypic response at 0.1μM, 
while comparable doses of vemurafenib and PD153035 have minimal phenotypic effect and do not 
suppress proliferation (data not shown).      
The preliminary evidence from the drug stress assay points to melanoma release of a pro-
inflammatory secretome, while Obenauf et al., 2015, reported ~2-fold increase in TGFβ2 and ~5-
fold increase in MCP1 using 0.1μM vemurafenib. Thus, given that the results from the drug-stress 
assay trend, and reports that melanomas release TGFβ with rounding, metastatic potential, and 
invasion both in vitro and in vivo (Cantelli G et al., 2015), we sought to determine whether CAFs 





Figure 11: Analysis of therapy induced secretome 
(A) Heat map showing log fold change of gene induction after 6 and 48hr of treatment from Obenauf et al. 
2015 (GEO: GSE64671). (B) Ingenuity pathway analysis of selected gene set shows suppression of tumor 





Figure 12: Drug stress induces the activation of TGFβ and inflammation pathways  
(A) Schematic of drug stress assay and downstream analysis (B) Q-PCR of targeted genes show that EGFR 
(1μM PD153035), BRAF (1μM vemurafenib) and MEK (0.1μM selumetinib) drives a therapeutic stress 
response in A375 and increase in TGFβ related genes and pro-inflammatory MCP1. Data are presented as 
mean ± s.e.m. 
(B) 
 
The presence of vemurafenib, PD153035 and selumetinib in static cultures does not drive 
αSMA+ activation in normal fibroblasts or CAF cell lines despite cell line variations in αSMA+ at 
steady state (Figure 13). Components of the bioactive drug-stressed secretome from A375 
conditioned media (CM) induces subsets of the αSMA+ CAFs and normal fibroblasts (TP1170), 
(Figure 14). Interestingly, despite originating from the same patient and localized tumor site, 
50236 distant CAFs exhibit more αSMA+ induction in comparison to the 50236 adjacent CAFs. 
(Figure 13-14). Thus, we examined how CAFs responded to melanomas with and without drug 
stress. 
The indirect coculture strategy is depicted in schematic form. Briefly, fibroblasts 
established from human samples and primary melanomas were seeded in transwell coculture with 
melanomas in the presence of a therapeutic stressor. Where indicated, fibroblasts were pretreated 
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with clinically relevant TGFβR inhibitor vactosertib or SB431542, and fibroblast growth factor 
(FGF) receptor BCJ398. After washing, therapy sensitive melanomas A375 or metastatic WM1158 
cells were seeded and EGFR, BRAF, or MEK with-or-without TGFβR/FGFR inhibitors were 
added after 24 hours (‘Day 2’) and cocultures were allowed to interact for 72hr (Figure 15A). This 
system utilizes 0.4μm filters that do not permit transwell invasion or cell-cell contacts.   
 
 
Figure 13: Fibroblasts tolerate small molecule inhibitors 
Fibroblasts and CAFs show little induction of αSMA+ pathways in response to small molecules targeted to 
melanoma (n = 3 biological replicates). A representative image is shown for each condition at 72hrs. 
Vehicle low serum (2%FBS) and 1μM vemurafenib, PD153035 and selumetinib in low serum media.  




Figure 14: The drug-stressed secretome drives fibroblast activation 
Fibroblasts and CAFs react to drug-stressed conditioned media (CM) in static monoculture. Induction of 
αSMA+ is observed in response to melanoma CM with vehicle while small molecules targeted to melanoma 
elicit obvious CAF and fibroblast responses. CM conditions: Vehicle low serum (2%FBS) and 1μM 
vemurafenib, PD153035 and selumetinib in low serum media (n=3 biological replicates). A representative 




Figure 15: Therapy inflammation leads to fibroblast activation via the TGFβ pathway 
(A) Schematic of drug stress cocultures and timeline to end point analysis after 72hrs. (B) Melanoma in 
coculture with normal, tumor associated, and patient derived CAFs does not induce αSMA. (C) Inhibition 
of MEK(i) in melanoma drives stress secretome and αSMA+ fibroblast and CAF inflammation. (D) Pre-
treatment to block TGFβR1/ALK5 (10μM SB431542) prior to MEK inhibition prevents TGFβ activation 
of αSMA in fibroblasts © Blocking FGFR with (1μM BCJ398) partially activates αSMA+ fibroblast and 
CAF inflammation. A representative image is shown for each condition at 72hrs (n=3 biological replicates 
per condition, TP004 n=2 biological replicates). Original magnification 10x. Scale bar – 100μm. 
 
Melanomas do not appear to activate αSMA+ CAFs when there is an absence of therapeutic 
stress (Figure 15B), however the addition of MEK inhibitor stimulates drug stress and leads to the 
activation of αSMA+ in normal, CAF and primary patient derived fibroblasts (Figure 15C). The 
response in terms of αSMA+ induction is heterogenous and varies by tissue ontogeny. There are 
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also discrepancies in terms of fibroblast proliferation evidenced by the quantity of cell nuclei per 
field, despite controlling for initial seeding density.  
Given that TGFβ is transcriptionally induced during drug-stress and released from 
melanoma during invasion, we next examined if TGFβRI/ALK5 inhibitor SB431542 could prevent 
αSMA+ CAF induction in MEK stressed melanoma coculture. Overnight pretreatment with 10μM 
SB431542 effectively blocked fibroblast and CAF αSMA expression (Figure 15D). The most 
dramatic response in normal neonatal fibroblasts is contrasted by fixed responses in CAFs which 
are phenotypically distinct and less plastic in response to TGFβ blockade.  
Interestingly, Bordignon et al., report that TGFβ inhibition in fibroblasts results in 
activation of the fibroblast growth factor (FGF) signaling axis. The authors observed activation of 
TGFβ signaling when treated with FGF inhibitor BGJ398, resulting in αSMA expression that was 
associated with squamous cell carcinoma EMT and invasion. Conversely, TGFβ inhibition led to 
FGF activation that is more closely with CAF stimulation of macrophage inflammation 
(Bordignon et al., 2019). This report led us to examine the effect of FGF inhibition in our transwell 
coculture system where we observed that blocking FGF stimulates CAFs, even in the absence of 
drug stress. The addition MEKi to BGJ398 treated fibroblasts serves to further the activation and 
expression of αSMA regardless of the stromal cell type (Figure 15E, Figure 16 – right).  
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Figure 16: Clinical inhibitor of TGFβ blunts while FGFR activates CAFs  
(A) Pretreatment of CAFs with clinically relevant TGFβ inhibitor vactosertib (1μM, TEW-7197) does not 
drive αSMA activity and suppresses CAF transformation during MEKi induced melanoma stress (‘MEKi 
+ A375S’). (B) Conversely, inhibition of FGFR drives atypical αSMA activation in static-coculture and 
augments CAF transformation in drug-stressed cocultures. A representative image is shown for each 
condition at 72hrs (n=3 technical replicates). Original magnification 10x. Scale bar –  
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3.2.3 Drug-stressed release of TGFβ supersedes immune inflammation in CAF activation 
Coupling our findings to Obenauf et al., regarding the release of CCL2 in addition to TGFβ 
during drug-stress, we hypothesized that immune cells which are also depots for TGFβ, may drive  
Figure 17: Immune inflammation does not appear vital for in vitro CAF transformation 
(Row 1): The presence of MEKi (1μM selumetinib) does not disturb the quiescent stromal environment in 
CAFs and normal fibroblasts. (Row 2) The addition of uninflamed melanoma to coculture in the absence 
of drug (Row 3) and immune component does not drive CAF activation. (Row 4) Addition of MEKi induces 
pro-inflammatory secretome of melanoma leading to αSMA activation regardless of an immune 
component. A representative image is shown for each condition at 72hrs (n=3 technical replicates, n=2 
melanoma cell lines). Original magnification 10x. Scale bar – 100μm  
 
inflammation and in vitro CAF activation. To model these interactions, 1.5x104 human peripheral 
blood monocytic cells (THP-1) were added to the both the upper and lower transwell 
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compartments, representing ~15% of the total cell population. After plating immune cells on the 
same day as melanomas, cocultures proceeded as indicated (Figure 15A). Having prior established  
that small molecules and uninflamed melanomas do not appear to activate αSMA in CAFs (Figure 
17, Row 1-2), the addition of immune cells to static cocultures and the lack of αSMA induction in 
CAFs was anticipated (Figure 17, Row 3). However, the innate immune component was expected 
to contribute to CAF activation given the data showing CCL2 spikes in drug-stressed melanoma. 
Nevertheless, there was no apparent increase in inflammation and αSMA+ CAFs in A375 and THP1 
coculture during MEKi. In fact, the level of CAF activation appears comparable, if not less than 
what was observed in MEK inhibited A375 with melanoma alone (Figure 17, Row 4 & Figure 
15C).     
Given that immune cells do not appear necessary to drive αSMA+ CAF expression, total 
cell actin was stained to assess actin stress fibers which are a hallmark of myofibroblasts. 
Interestingly, there appears to be an evolution in fibroblast actin stress fiber expression (Figure 
18). Fibroblasts and CAFs are positive for actin stress fibers in the presence of MEKi (1μM 
selumetinib) but remain low in expression of CAF marker αSMA (Figure 17-18, Row 1). In the 
presence of uninflamed melanomas, a burst in proliferation is evidenced by the compaction of 
stress fibers as well as the morphological emergence of cell alignment in normal fibroblasts and 
CAFs (Figure 18, Row 2). The addition of naïve innate immune cells which do not trigger αSMA 
had limited impact on actin stress fibers (Figure 18, Row 3). However, melanoma and immune 
drug-stressed cocultures do lead to αSMA+ CAFs (Figure 17, Row 4). These same cells also appear 
elongated and compacted with fibrillar organization of actin stress fibers; a common feature in 
fibrotic tissues (Figure 18, Row 4). Nearly all fibroblasts and CAFs are positive for actin stress 
fibers whereas subpopulations of CAFs are double positive for αSMA. Alternative activation of 
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CAF has also been observed during in vitro TGFβR and FGFR inhibition of patient fibroblasts 
independent of the genetic differences between individuals (Storey JD et al., 2007).  
 
 
Figure 18: Actin stress fibers are activated but do not correlate with αSMA CAF 
(Row 1) Fibroblast and CAFs have actin stress fibers in static coculture with MEKi (1μM selumetinib). 
(Row 2) Stress fiber compaction is evident with phenotypic and morphological responses to bidirectional 
signaling in coculture. (Row 3) Innate immune component does result in increased inflammation or stress 
fiber formation. (Row 4) Evidence of remodeling emerges with αSMA CAFs (Figure 17, Row 4) with stress 
fibers and organization of fibrillar arrangements. A representative image is shown for each condition at 




CAFs are reported to exist in mutually exclusive states wherein TGFβ controlled gene 
expression drives αSMA, hallmarked by immune suppression and fibrotic ECM synthesis, while 
FGFR states oppose TGFβ to promote immune inflammation (Bordignon et al., 2019). This 
finding implies CAFs can coexist in heterogenous populations with αSMA+ TGFβ responsive cells 
driving differential responses to growth factors and cytokines in nearby negative αSMA(neg) cells. 
However, αSMA(neg) fibroblasts appear responsive to the pleiotropic signals in cell culture which 
manifests via the activation of stress fibers and proliferation. Still, inhibition of TGFβ in drug-
stressed cocultures most directly impacts the expression of αSMA in fibroblasts.  
In light of αSMA and actin stress fiber expression patterns observed of in vitro, which was 
also confirmed with metastatic melanoma WM1158 (data not shown), the necessary role of drug 
induced TGFβ expression and downstream role in activating αSMA appears evident. To confirm 
that TGFβ release is the result of drug-stress, the RNA-seq dataset for the therapy induced 
secretome by Obenauf et al., was examined for vemurafenib resistant A375© melanoma from in 
vivo tumors. The hypothesis driving this query was that drug-resistant melanomas lacking an 
inflammatory secretome would fail to activate αSMA CAFs due to the absence of TGFβ.   
The induction of TGFβ2 and TGFRβII in therapy sensitive A375S tumors correlated with 
the in vitro A375S secretome (Figure 19A, 11A). However, vemurafenib induced expression of 
genes correlating to growth factors, the TGFβ pathway, and EMT/-drug resistance in A375S cells 
is virtually absent in vemurafenib resistant melanoma (A375R) (Figure 19A). Interestingly, there 
is a detectable 1.26-fold increase of EGFR transcript in A375R which correlates to an observed 
increase in protein expression for PD15035 (P) and vemurafenib (V) resistant A375R relative to 
the sensitive parental line (S) (Figure 19B, left). A similar trend in EGFR expression is observed 
in vemurafenib resistant W983B and in PD153035 resistant WM1158 (Figure 19B, middle & 
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right). In most cases where EGFR is upregulated, phospho-ERK trends while phospho-AKT 
induction is transient. From the expression dataset, it appears that downregulation in TGFβ 
transcription is associated with an uptick in EGFR.  
 
Figure 19: Drug-resistance blunts the in vivo therapy induced secretome 
(A) Heat map showing log fold change of gene induction between sensitive A375S and resistance A375R 
treated xenograft tumors Obenauf et al. 2015 (GEO: GSE64671). (B) Protein analysis of PD153035 (P), 
vemurafenib (V) and parental (P) melanoma. 
 
The limited induction of the TGFβ pathway of A375R tumors trends with the suppression 
of genes linked to the EMT pathway. There is a reduction in MITF and AXL which Tirosh et al., 
linked to drug resistance, in addition to epithelial marker E-cadherin and anti-invasive DCN and 
pro-invasive TNC (Figure 19A, ‘A375R’). Thus, the pathways that feed forward in establishing 
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proliferative ability, suppression of cell cycle control, EMT/-drug resistance, and TGFβ appear to 
turn off in the absence of vemurafenib stress.  
To test how therapy-resistant melanomas impact CAFs, melanomas were cultured in the 
presence of small-molecule inhibitors for ~8weeks. Clones were selected based on phenotype and 
response, expanded and analyzed for protein expression. (Figure 19B). Resistant clones displaying 
stable increases in growth factor expression and constitutive activation of ERK and AKT were 
used to determine if drug-resistant melanomas can inflame CAFs.  
Cocultures with vemurafenib A375R melanomas show little activation of αSMA in normal 
and cancer-associated fibroblasts in the absence of drug-stress (Figure 20, Row 1).  The addition 
of vemurafenib (BRAFi) to resistant cells also fails to drive the release of the drug-stress 
secretome. However, inhibition of BRAF in melanoma paradoxically elicited a weaker induction 
of αSMA in fibroblasts in comparison to selumetinib and PD153035 at the same and is 
concentration (Figure 21). This finding prompted the use of selumetinib throughout this study. 
The use of MEK inhibitors is also of particular relevance for vemurafenib resistant 
melanoma, especially given that combined BRAF and PI(3)K/AKT/mTOR is reported to control 
the Given that the reactive secretome is activated in melanoma in both a drug-specific and dose-
dependent situation – this secretome varies slightly between in vitro and in vivo conditions. We 
elucidated from the therapy-stressed secretome that the TGFβ pathway is consistently induced 
during drug-stress. In cocultures, this TGFβ containing secretome consistently activates αSMA+  
pathways in fibroblasts driving conversion to CAFs (confirmed by western analysis – Figure 22). 
This activation proceeds predominantly through TGFβ, which when blocked using small 






Figure 20: Drug-resistant cells lack an inflammatory secretome 
Fibroblasts and CAFs show little induction of αSMA+ pathways in response to small molecules targeted to 
vemurafenib resistant melanoma (n = 3 technical replicates). A representative image is shown for each 
condition at 72hrs. Vehicle low serum (2%FBS) and 1μM vemurafenib and selumetinib in low serum 





Figure 21: Targeted inhibitors drive differential in vitro coculture CAF responses 
(Row 1) Inhibition of BRAF using 1μM vemurafenib drives αSMA expression while (Row 2) 1μM 
PD153035 and (Row 3) selumetinib induce marked increases in αSMA expression in normal fibroblasts 
and CAFs in coculture with A. A representative image is shown for each condition. (n=3 technical 
replicates). Original magnification 10x. Scale bar – 100μm. 
 
Alternative TGFβ activation was observed in FGFR suppressed fibroblasts, which is linked to 
TGFβ and FGF dualism in regulating CAFs between pro-fibrotic and immune inflammatory 
phenotypes. This was exemplified here by CAFs maintaining actin stress fibers while 
subpopulations of CAFs were observed to be double positive for αSMA+ and stress fibers. 
Furthermore, CAF responses are not uniform in terms of SMAD activation and αSMA induction 
in response to TGFβ highlighting the challenges associated with targeting these heterogenous 
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populations. However, human data and animal studies (Figures 4-9) show that αSMA induction 
occurs simultaneously in micrometastatic melanoma outgrowth and inflammatory ECM 
remodeling. Therefore, we sought to determine how CAFs drive melanoma outgrowth in vitro 
using dense-tissue mimics referred to as spheroids.    
 
Figure 22: Western analysis of TGFβ and cell stress induction of αSMA in CAFs 
(A) TGFβ induces intracellular SMAD2 to activate the pathway and expression of αSMA in normal and 
cancer-associated fibroblasts while pre-treatment to block TGFβR1/ALK5 (10μM SB431542) after 24hrs 
abolishes pSMAD2 and αSMA. (B) MEK inhibition of A375 in coculture with fibroblast and CAFs drives 
activation of αSMA which is suppressed by varying degrees with TGFβR1/ALK5 (10μM SB431542) after 
24hrs. (n=2 technical replicates per condition).  
3.2.4 Cancer-associated fibroblasts drive in vitro melanoma outgrowth 
There are multiple studies linking the presence of CAFs to the progression of primary 
tumors, including melanoma (Kaur et al., 2015). To ascertain how CAFs impact melanoma 
outgrowth in combination with the drug-stressed secretome, a modified transwell coculture system 
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was utilized. Briefly, to examine the effect of inflamed fibroblasts on melanoma invasion, a 
spheroid coculture system wherein fibroblasts and CAFs are seeded directly on to the transwell 
membrane followed by the deposition of collagen into which a spheroid is embedded, was 
designed (Figure 23A). 
After embedding, spheroids were allowed to interact with the soluble secretome, both with 
and without drug-stress. Invasive outgrowth was measured after 72 hours. Metastatic WM1158 
spheroids outgrow ~4-fold in comparison to the Day 0 area in the absence of fibroblasts or CAFs 
(Figure 23B).  That addition of LPS/EGF to stimulate EGF mediated motility in these EGFRHI 
expressing cells resulted in 5.3-fold increase and 37% more outgrowth compared to no 
stimulation/- no fibroblast control. However, this was not statistically significant.  
Cocultures with normal fibroblast (TP1170) suppressed outgrowth (3.25-fold, Day 3) 
relative to the unstimulated and stimulated controls (Figure 23B, ‘nrml fib’). This is consistent 
with reports that co-implantation with healthy fibroblasts results in tumor stasis (Kullari R., 2016). 
Young CAF, 50306 tumor distant and adjacent drive 4.9 and 5.3-fold increase in invasion, 
respectively. This effect is comparable to the LPS/EGF inflammatory stimulus control. Lastly, 
aged CAFs, 50236 drive a 5.13 and 6.33-fold increase in invasion between tumor distant and 
adjacent, respectively. Representative images of spheroid invasion at Day 3 show how CAFs 
augment melanoma invasion (Figure 23C). A related study by Kaur et al., reported that melanoma 
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Figure 23: Cancer associated firboblasts augment the invasion of metastatic melanoma 
(A) Schematic timeline of co-culture invasion assay. (B) Invasion of melanoma spheroids in coculture with 
normal and cancer associated fibroblast cell lines derived from an aged patient. Invasion was quantified by 
ImageJ (n=2 fibroblasts per group, n ≥ 3 spheroids per group; Day 3, ANOVA  s.e.m., P< 0.01 ***, 
0.0001 ****; Bartlett’s statistic corrected, R2 = 0.85 – original magnification 4x). Adj, tumor adjacent; Dis, 
tumor distant. (C) Representative images of 72hr outgrowth for selected conditions. Scale bar – 400μm.  
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CAFs, which are disproportionately common in older individuals, secrete a proto-oncogene-INT 
1 (WNT1) antagonist secreted frizzled related protein 2 (sFRP2). This molecule drives signaling 
cascades that alters β-catenin thereby driving pro-epithelial MITF down to promote invasion. This 
bi-directional signaling loop is purported to increase in aging and ultimately drives metastasis of 
melanoma (Kaur et al., 2015). Although the focus here is not on aging, and instead on 
inflammation driven remodeling of the tumor-ECM, synergy or plasticity between these pathways 
during progression cannot be ruled out. Our results demonstrate that normal fibroblasts suppress 
invasion while CAFs promote melanoma outgrowth. The tumor-stroma coculture spheroid model 
supports our initial hypothesis that bi-directional signals in the TME converge to drive pro-
tumorigenic programs. Based on our previous findings demonstrating that small molecules drive 
stress in melanoma and inflame the stroma, addition of MEK inhibitor to cocultures was tested to 
determine if CAFs promote melanoma invasion.  
The growth of A375 spheroids, which form a loose spheroid, show moderate outgrowth in 
culture with normal fibroblasts and CAFs on Day 3 (Figure 24A, i). Addition of 1μM MEK1/2 
inhibitor selumetinib suppressed Day 3 invasive outgrowth relative to untreated control and 
resulted in smaller spheroids, (p<0.05) (Figure 24A, ii). Conversely, highly metastatic WM1158 
which are rounded in 2D and amoeboid during invasion, readily invade collagen (Figure 24B, i). 
The same MEK suppressive effect on invasion also occurred in WM1158 spheroids, which were 
observably smaller, though this was not significant (n.s.) with respect to the untreated control 
(Figure 24B, ii). WM1158 spheroid cocultures with normal fibroblasts also show comparable 
outgrowth to Day 3 untreated invasive outgrowth from the assays in (Figure 23B, i).  Therefore, 
the reduction of invasion and smaller spheroids observed in this assay can be reliably attributed to 
MEK inhibition.  
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Figure 24: Inhibition of MEK in melanoma limits outgrowth but not invasion 
(A) Invasion of malignant A375 and (B) metastatic WM1158 spheroids in co-culture with normal fibroblast 
(TP1170). (C) A375 and (D) WM1158 spheroids cancer associated fibroblast 50236 Adj. and  A375 and 
(F) spheroids with 50236 Dis. (cell lines derived from an aged patient, 50236). Invasion was quantified by 
ImageJ (n=2 fibroblasts per group, n ≥ 3 spheroids per group; Day 3, Student’s unpaired t-test  s.d. P< 
0.001 ***, 0.0001 ****; Day 3 Welch’s correction, original magnification 4x). Representative images of 
72hr outgrowth for selected conditions. Adj, tumor adjacent; Dis, tumor distant, © = control, ii = MEKi. 
Scale bar – 200μm.  
 
Aged tumor adjacent CAF, 50236 Adj., had limited impact on untreated malignant A375 
outgrowth while MEKi prevented outgrowth of the spheroid (Figure 24C, i-ii). In contrast, 
cocultures of 50236 Adj. and WM1158 spheroids resulted in greater than 2-fold increase in 
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invasive area compared to MEKi treated spheroids (Figure 24D, i-ii). The same trends were 
consistent for both A375 and WM1158 spheroid cocultures with 50236 Dis., (Figure 24E-F, i-ii). 
Thus, inhibition of MEK limited spheroid outgrowth for both A375 and WM1158 spheroids in all 
conditions, despite the pro-inflammatory secretome and CAF activation. However, MEK 
inhibition of melanomas does not prevent invasion. Instead, MEKi appears to activate a subset of 
invasive cells while restricting growth of the primary mass. A375 spheroids shift from collective 
outgrowth in untreated conditions to invasive sentinel cells due to MEKi induced stress. For both 
cell types, the result of MEKi is smaller tumors with more invasive cells at the periphery. 
Therefore, MEKi induced stress in melanoma limits outgrowth, seemingly independent of CAF 
activation during the 72hr assay. Prompted by this finding and results from our in vivo studies, we 
hypothesized that ECM remodeling may precede the contributions of a bioactive and inflamed 
stroma. Immunohistochemical evidence here showing ECM-remodeling during the early phases 
of micrometastatic outgrowth suggested that ECM may have key roles in regulating invasion.  
3.2.5 The inflamed stroma produces pathological matrix that promotes invasion 
We have previously reported on the turnover of matrix that occurs during melanoma 
progression.  During invasion the proportion of homeostatic proteins such as SLRPs and collagens 
are diminished while immature matrix is upregulated (Hood BL et al., 2010). These findings 
prompted experiments to build on our understanding of how inflamed stroma may modify 
expression of certain matrix proteins to promote melanoma invasion.  
In order to probe the effects of matrix on melanoma invasion, we constructed collagen 
plugs to study the vertical migration of melanoma (by courtesy of Jelena Grahovac). Briefly, 
control collagen gels and collagen mixed with decorin (DCN) or TNC (tumor-ECM mimic) were 
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prepared to model the pathophysiological contributions of select ECM proteins that accompany 
fibroblast inflammation. Metastatic WM1158 melanoma were seeded on top of collagen (COL1), 
COL1-DNC, COL1-TNC, and COL1-DNC-TNC.  
 
 
Figure 25: Normal ECM halts – while Tumor ECM – promotes invasion 
(A) WM1158 invasion in collagen gels with representative ECM proteins to mimic normal and tumor ECM 
synthesized by CAFs. (B) Invasion analysis to detect cell volume and detachment.  
 
 
WM1158 readily invaded into 3mg/ml COL1 gels via collective (yellow) and single cell 
invasion (green) (Figure 25A-B, Row 1). The addition of anti-invasive and tumor inhibiting DCN 
(4μg/ml) into collagen gels suppresses collective invasion compared to control COL1 (Figure 
25A-B, Row 2). Conversely, the addition of tumor promoting TNC (4μg/ml) to collagen 
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significantly promotes WM1158 invasion (Figure 25A-B, Row 3). This agrees with our previous 
work wherein genetic transformation of radially invasive WM983A melanoma with EGFL-
containing TNC was sufficient to drive vertical invasion with TNC localized to the invasive front 
(Grahovac J et al., 2013). Enrichment of TNC at the invasive front has been reported in 
micrometastatic breast nodules and reviewed by Lowy et al. (Oskarsson T et al., 2011; Lowy 
CM et al., 2015). Here, we observe enrichment of TNC in vivo within micrometastases, while 
COL1-TNC gels definitively shows that this anti-adhesive protein promotes single cell invasion; 
detached cells (green) and collective tumor mass (yellow) as quantified by Imaris software (Figure 
25B, Row 3). Addition of DCN into pro-invasive COL-TNC gels dramatically suppressed 
WM1158 invasion (COL-DCN-TNC) (Figure 25A, Row 4). Decorin also limits single cell 
invasion (green) and collective invasion despite the presence of TNC (Figure 25B, Row 4).  
To validate these results in a more representational melanoma microenvironment, we tested 
the invasion of WM1158 cells in three-dimensional organotypic skin organ cultures (SOCs). These 
SOCs develop forming a cornified epidermis, granular and spinous layer, over top of a developing 
basal keratinocyte layer which generates the basement membrane ©. Normal neonatal fibroblasts 
(TP1170) are embedded into 3mg/ml collagen gels to form the dermal compartment (D) (control 
SOC, Figure 26A). Seeded WM1158 cells invaded into the dermal compartment of SOCs within 
20-day time frame, both collectively and as detached cell clusters (Figure 26B). The addition of 
DCN (4μg/ml) into the dermal compartment prevented melanoma cells from invading into the  
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Figure 26: Tumor ECM drives progression while normal ECM blocks invasion 
(A) Collagen control skin matures with development of an epidermis ©, basal keratinocytes, and dermis 
(D). (B) The addition of WM1158 melanoma (M) to collagen (CTRL) skins (C) Mature matrix protein 
DCN blocks WM1158 invasion. (D) Tumor-ECM matrix protein TNC in collagen drives marked invasion. 
© Mature matrix DCN blocks the tumor promoting effect of TNC. (F) Changing the tumor-ECM ratio 2:1 
TNC to DCN re-establishes invasion into the tumor stroma. A representational image is shown for each 
condition.  
dermis. The bulk of the tumor growth appears confined to the epidermis (Figure 26C). Conversely, 
the addition of TNC (4μg/ml) markedly induced melanoma invasion into dermis, with advancing 
collective invasion (Figure 26D). Based on the stochiometric ratios used here, tumor inhibiting or 
promoting ECM can be titrated to regulate invasion in a dose-dependent manner (1:1, DCN: TNC 
ratio 4μg/ml each (w/w)). Interestingly, WM1158 in COL1-DCN skins exhibited stalled invasion, 
but remained proliferative in the epidermis © (Figure 26C). Increasing the TNC:DCN ratio 2:1 
results in WM1158 that respond to the pro-invasive effects of TNC (4μg/ml: 8μg/ml, (w/w)). 
Based on these findings, the role of ECM in acting as a barrier to invasion is apparent. 
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Experimentally remodeling the ECM with wound healing protein TNC to mimic the tumor ECM 
promotes rapid advancing melanoma. This can be halted via the incorporation of mature, anti-
invasive, ECM molecule DCN which suppresses tumor progression. This is of interest given that 
CAFs in drug-stressed spheroid cocultures did not appear to blunt the cytotoxic effect of MEK 
inhibition or single cell invasion. However, the use of ECM molecules synthesized by normal 
fibroblasts such as DCN, or TNC by melanoma and CAFs exert an immediate effect on melanoma 
invasion and progression. Taken together, there is evidence to suggest that ECM remodeling and 
altered signaling likely converge to influence multiple facets of melanoma invasion and resistance.  
3.3 Discussion  
3.3.1  Drug resistance in melanoma  
Common treatments such as chemotherapy, targeted therapies and even immunotherapy 
regimens confer modest survival benefits to patients with metastatic melanoma. Primary lesions 
clinically exhibit a robust response that is lost overtime and generally muted in combating 
metastasis. Briefly, vemurafenib targets the commonly mutated BRAFV600E mutation which is 
present in approximately 50% of melanomas (Cancer Genome Atlas Network, 2015). However, 
evolving tumors adapt to treatment and develop resistance that drives partial responses in most 
patients (Sosman JA et al., 2012; Chapman PB et al., 2011; Flaherty KT et al., 2010). 
Resistance is primarily achieved by mutation or convergent alternative activation of multiple 
signaling axes.  
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In melanoma, the mitogen activated protein kinase (MAPK) pathway proceeds via 
activation of rapidly accelerated fibrosarcoma serine/threonine kinase (RAF; ARAF, BRAF, c-
RAF) which signal downstream to extracellular-regulated kinase (ERK) and phosphoinositide 3-
kinase (PI(3)K-AKT-mTOR) or AKT. This cascade activates multiple tumor processes that drive 
initiation, progression and therapy resistance (Lito P et al., 2013).  The development of FDA 
approved inhibitors vemurafenib, dabrafenib (BRAF), and trametinib (MEK) which are often used 
to shut this pathway down in melanoma, also lead to the alternative activation of non-genetic 
programs that are now gaining appreciation as drivers of resistance.  
Therapeutically targeted melanomas are antagonized by drugs (incl. chemotherapy) 
resulting in external and internal stimuli that lead to the activation of cell stress. This stress triggers 
a broad range of cellular functions. Vemurafenib stress induces endoplasmic reticular stress and 
mediated apoptosis in melanoma while also driving activation of a therapy-induced secretome that 
promotes resistance and progression (Beck D et al., 2013; Obenauf AC et al., 2015). The therapy-
induced stress secretome contains multiple inflammatory growth factors and cytokines that results 
in tumor self-seeding and recurrence (Kim MY et al., 2009). This prompted the investigation of 
how the drug-stressed secretome stimulates an inflammatory matrix and whether this promotes 
metastatic melanoma.  
3.3.2  The complex tumor contexts of TGFβ  
This thesis identifies the TGFβ-SMAD pathway as a driver of CAF activation and ECM 
remodeling in the TME. This process is outlined as a graphical abstract (Figure 27). Briefly, small 
molecule inhibitors were shown here to drive the inflammatory transcription of TGFβ, macrophage 
chemotactic protein 1 (MCP1/CCL2), in addition to the first report of a BRAF therapy-induced 
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secretome. This induced secretome contains intracellular SMADs, latent TGFβs, and genes related 




Figure 27: Graphical abstract of TGFβ driven inflammation and melanoma progression 
Proposed TGFβ signaling loop involved in the activation of CAFs and proposed inhibitory strategies for 




pathological activation of cancer-associated fibroblasts (CAFs). This process, initiated by TGFβ 
binding to TGFβRI/II, activates intracellular phosphorylation of SMAD2/3 which forms 
heterotrimer complexes with SMAD4. These complexes transit the nucleus, driving genetic 
programs that impact the maintenance of CAFs, ECM synthesis and a CAF secretome. These 
pleiotropic signals manifest in the formation of complex and drug resistant TMEs.  
Transforming growth factor βeta paradoxically has both tumor suppressive and supportive 
functions in cancer. The TGFβRI/II receptors are not directly coupled to pro-apoptotic pathways 
as we did not observe in vitro lethality in melanoma and CAF responses to TGFβ1. In fact, 
SMAD2/3 nuclear localization in A375 occurred 24-48hrs after treatment TGFβ1 and suggesting 
that TGFβ is not a key survival signal in melanoma (data not shown). Instead our data shows that 
TGFβ1elicits a rapid induction of p-SMAD in normal and CAF cell lines leading to reversible 
αSMA expression when blocked with TGFβRI/II inhibitors SB431542 or vactosertib. In cancer, 
cells are suspected to undergo selective pressure imposed by TGFβ exposure resulting in clones 
that can then undergo TGFβ-induced EMT (David CJ et al., 2018). Though the drivers of 
desensitized TGFβ responsive cancer cells are unclear, PI(3)K/AKT/mTOR (AKT) signaling 
stimulated by growth factors from the tumor stroma are emerging as candidates. Obenauf et al. 
reported that combined inhibition of RAF and AKT effectively disrupts outgrowth of drug resistant 
melanomas (Obenauf AC et al., 2015). However, the penetrance of these genetic treatments is 
limited owing to inflammation that spurs increasingly complex stromal networks.  
Our results demonstrate that the stroma has varied impact and function in response to drug-
stressed melanoma. Cocultures of melanoma and CAFs appears to elicit CAF activation primarily 
though soluble TGFβ. Future studies should probe whether specific SMADs trigger this function 
in CAFs using siRNA for transient studies. Stable knockdowns using the pLKO-shRNA vector 
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targeted to TGFβRI/II receptors in CAFs will deconvolute whether αSMA expression is exclusive 
to the TGFβ pathway. This is of particular importance as TGFβ has coreceptors in addition to the 
pleiotropic signaling capacities and modularity of this pathway.  
Within the context of how TGFβ impacts stromal-mediated progression, findings from this 
thesis point to CAFs as the primary driver of metastatic melanoma. Our findings show a 
concomitant increase EGFR in higher and metastatic grade malignancy. Metastatic melanomas are 
also reported to secrete ~2-fold more TGFβ (pg/ml) in vitro compared to low-grade cell lines such 
as WM983A/B. In the context of melanoma, TGFβHI expression in localized invasion activates 
SMAD2/4 and leading to CITED1 transcription. CITED1 expression was associated with non-
proteolytic amoeboid rounding. This TGFβ phenotype displays increased in vitro and in vivo 
invasion and poor outcomes in patient samples (Cantelli G et al., 2015). Our established studies 
have shown that metastatic WM1158 can invade via this amoeboid phenotype (Grahovac J et al., 
2013). This thesis also indirectly establishes that TGFβ is also released during therapy-induced 
cell stress cocultures. Thus, there is a need to investigate how melanoma responses to TGFβ shift 
from the untreated to therapeutic situation.  
3.3.3  Alternative TGFβ reprogramming in the stroma 
Both normal and cancer-associated fibroblasts appear highly responsive to TGFβ in 
coculture. This dissertation establishes that robust responses to TGFβ and subsequent CAF 
activation results in αSMA expression. However, the response is heterogenous with diffuse actin-
stress fiber expression with only subpopulations of double positive αSMA+ CAFs, a feature which 
varies between fibroblast cell lines. These double positive cells likely result from a TGFβ dominant 
response, while αSMA(neg) are activated and maintained by FGF. The bioactive CAF secretome is 
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contains both growth factors, wherein TGFβ CAFs are pro-fibrotic and associated with invasive 
SCC, while FGF CAFs are found in non-desmoplastic regions with greater macrophage infiltration 
(Bordignon P et al., 2019). The discrepancy between actin stress fibers and αSMA+ could feasibly 
result from the dual invocation of these pathways. Dominant negative (DN) studies by Bordignon 
et al., revealed the dynamic reciprocity that exists between TGFβ and FGF signaling in CAFs. 
DNTGFβR2 resulted in the activation of FGF responses and expression of inflammatory cytokines 
(CXCL1, CXCL10, CXCL11) and macrophage activation associated with loss of αSMA. 
Suppression DNFGFR1 drove CAFs to regain αSMA. This is of particular importance given that 
astrocytes which are the representation stromal component in brain tissue are shown to recruit 
CXCR3+ melanomas through CXCL10 secretion. Our findings show that infigratinib (FGFRi) 
indeed drives αSMA and supports a dualism between FGF and TGFβ. Whether dual treatment 
with FGFRi and TGFβRi suppress αSMA needs to be examined. However, given the striking 
inhibition of αSMA with TGFβRi alone, combining treatments addresses a separate issue that 
concerns both fibrosis and inflammation. Our coculture data supports the model wherein therapy-
sensitive cells boost αSMA expression in CAFs as αSMA was absent in BRAF and MEK targeted 
vemurafenib resistant melanomas. This finding was surprising given that A375R cells should 
remain sensitive to MEK and thus secrete stress-induced signals. The effect of immune 
inflammation was also absent in vitro despite transcriptional indications that MCP1 is highly 
induced from cell stress. This may be attributed the reductionist nature of these cocultures, thus 
additional assays in ex vivo 3D-skin organ cultures or in vivo studies are warranted. However, this 
may also indicate that immune inflammation is not essential to αSMA CAF activation. However, 
the data herein shows that drug and dose-dependent effects influence the composition of the drug-
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stressed secretome, which has downstream impacts on CAF phenotypes. This led additional 
studies to characterize how activated CAFs impact progression.  
3.3.4  The inflamed TME drives melanoma progression 
To ascertain the effect of CAFs on progression, modified cocultures with diminished cell-
cell contacts were utilized. CAFs had marked impact in promoting the invasive outgrowth of 
melanoma while the normal counterparts were moderately suppressive for 72hrs. The presence of 
CAFs from a young patient trended with a lipopolysaccharide/EFG inflammatory stimulus. Aged 
CAFs had an even greater effect in driving metastatic WM1158 outgrowth. Aged CAFs are 
reported to increase melanoma invasion and resistance through modified WNT/β-catenin and 
sFRP2 signaling that ultimately confers greater resistance to reactive oxygen species. Drug 
sensitivity was restored in melanoma after knockdown of sFRP2, which diminished spheroid 
expansion in vitro and melanoma metastasis in vivo (Kaur S et al., 2015). Given that MEKi had 
been shown to drive inflammation of αSMA CAFs in vitro, selumetinib was added to these 
cocultures. This was hypothesized to drive spheroid release of TGFβ and CAF activation, however, 
MEKi resulted in smaller spheroids and reduced invasion. Despite limited collective outgrowth of 
the spheroid mass, individual single cells were still invasive. Of more interest was evidence of 
MEK induced single cell invasion of A375 which routinely invade as a collective mass in the 
absence of drug stress. The single cells may therefore be more sensitive to TGFβ, suggesting 
plasticity within cell lines. TGFβ responsive squamous cell carcinomas (SCC) localize to the 
tumor-stroma interface in mice (Oshimiri N et al., 2015), while activated SMAD in complex with 
transcription factor AP1 (c-JUN, FOS) have been shown to impact ECM proteolysis (Qing J et al., 
2000). Thus, studies investigating the transcriptional status of highly invasive melanomas during 
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drug stress may provide insight and targets to blunt invasion. Moreover, the lack of CAF support 
during drug stress may also be attributed to the temporal nature of this assay, as multiple in vivo 
co-implantation xenograft studies have shown CAFs to promote progression. Interestingly, 
modified CAF responses may also tie back into immune inflammation in supporting a fibrotic 
TME. Thus, the seeming abject response of immune cells in coculture could be both contextual 
and require a longer time scale leading the pro-tumorigenic macrophages. Therefore, additional 
studies investigating whether CAFs can acquire an immunosuppressive phenotype in vitro within 
the context of melanoma and immune cells is of relevance. This is particularly salient as CAFs 
derived from patient tumors are reported to lose immunosuppressive genetic signatures in vitro 
(Tirosh I et al., 2016). Thus, 3D-skin organs were used to develop more representational 
microenvironments in which the bioactive ECM could be probed.  
Guided by the in vivo studies showing peri-tumor enrichment of αSMA in tenascin-C rich 
micrometastatic melanomas, we focused on tumor-ECM molecules as mediators of progression. 
The data leading up to this study had established an essential role for TGFβ in driving CAF 
activation, however the bioactive secretomes only provide partial insight into how inflammation 
drives metastatic melanoma. The ECM is an essential mediator of advancing melanoma and our 
prior studies had established a role of TNC in this process. Tumor-ECM and inflammatory TNC 
resulted in increased WM1158 invasion into collagen-TNC gels. Conversely, invasion was blunted 
in anti-invasive DCN collagen gels. Titrating these ‘stop-or-go’ ECM signals revealed that these 
representative normal and CAF associated ECM molecules may be therapeutically beneficial. 
Furthermore, these findings aid in explaining how normal fibroblasts suppress advancing 
melanoma, while CAFs support progression. TNC and DCN can bind and signal through EGFR 
with opposite outcomes. Select Epidermal Growth Factor-like (EGFL) repeats of TNC have been 
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shown to bind to the EGF binding pocket of EGFR (Iyer et al., 2007), while the DCN binding site 
in EGFR partially overlaps but is distinct from the EGF binding epitope (Santra M et al., 2002).  
We have previously shown that EGFL repeats of TNC promote melanoma cell 
invasiveness by increasing the ROCK activity and myosin-light chain phosphorylation in 
migrating cells, which leads to a shift in mode of motility from mesenchymal to amoeboid and 
allows greater flexibility in 3D microenvironment (Grahovac J et al., 2013).  Decorin could 
simply prevent this effect by competing for EGFR given that it has higher affinity for the receptor 
(Csordás G et al. 2000).  Alternatively, DCN could signal inhibition of migration through other 
receptors such as c-Met, PDGFR or IGF-1R (Grahovac J et al., 2014), all of which can 
independently influence melanoma invasiveness. DCN and TNC both bind Toll-like receptor 4, 
with seemingly opposite effects (Merline R et al., 2011; Midwood K et al., 2009).  TNC binding 
to TLR4 was shown to drive pro-tumorigenic M2 macrophage polarization (Piccinini AM et al., 
2016) and revealed by quantitative proteomics as a potential signature of fibrosis and lung 
adenocarcinoma progression (Gocheva V et al., 2017). Therefore, a natural moiety present in the 
skin, DCN is an attractive candidate for the development of anti-melanoma therapy. DCN targets 
multiple kinase receptors involved in cancer promotion in addition to EGFR (Csordás G et al. 
2000; Iozzo RV et al., 2011) and DCN gene delivery has already been shown to retard the growth 
of human tumors in immunocompromised animals (Reed CC et al., 2002) Thus, methods to 
restore normal ECM in place of tumor ECM may have a profound impact in limiting the 
dissemination of melanoma.  However, restoration of normal ECM will likely need to proceed 
through the reprogramming of CAFs.  Therefore, targeting molecules such as TGFβ to eliminate 
the TME will be as essential as targeting the tumor.  
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4.0 Potential Therapeutic Strategies: Targeting TGFβ and the inflamed TME 
The network of signals relayed between the tumor and stroma is both vast and intricate. 
This thesis has identified an underappreciated role for the off-target effect of TGFβ release into 
the TME during treatment. Transforming growth factor-β is secreted by stromal, immune and 
tumor cells and can bind ECM residing in a latent form. However, this cytokine and the ECM to 
which its binds evolve with the TME leading to tumor inhibiting effects that transition to promote 
tumors in advanced stages. Thus, targeting TGFβ, or cellular sources, in addition to the ECM that 
sequesters this protein, may have potential far-reaching therapeutic benefits in melanoma and 
metastatic disease.  
4.1  TGFβ regulatory and targetable functions 
There is still work underway to tease out mechanisms by which TGFβ mediates progression 
in melanoma while educating CAFs to reorganize and signal from the tumor ECM. The thesis 
shows that TGFβ is secreted into the TME to circumvent growth suppression and activate CAFs 
that potentially inhibit immunogenic cell death (ICD). Here, the bulk of secreted TGFβ was shown 
to result from drug-induced stress. Targeted small molecules (BRAF, EGFR and MEKi) used in 
the treatment of melanoma drove TGFβ release. However, mouse models of colorectal cancer 
(CRC) experimentally identified stromal TGFβ as a stimulator of CAF derived IL-11 that 
promoted CRC survival and metastasis to liver (Calon A et al. 2012). The release of TGFβ also 
acts to directly inhibit CD8 T-cell cytotoxicity (Thomas DA et al., 2005). In addition, TGFβ also 
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prevents tumor-infiltrating macrophages and neutrophils by promoting immunosuppressive 
activation (Novitskiy SV et al., 2012) (Figure 28-1).  
This has spurred the development of inhibitors of TGFβ targeted to TGFβ1, TGFβ2, 
TGFβ3, or type I and II TGFβR (Table 1). However, the pleiotropic signaling capacities of these 
molecules and downstream signaling cascades have made TGFβ a challenging target (Demaria O 
et al., 2019). Many of these strategies involve direct inhibition via TGFβRI antagonists or 
sequestration of TGFβ via bispecific ecto-domains and checkpoint blockade. This dissertation tests   
 
Table 1: Current Therapeutics against TGFβ (2020) 
Biologics 
Drug Phase Manufacturer Format 
Bintrafusp-alfa/ M7824 Phase 2/3 Merck, GSK 
Bifunctional “TRAP” Fusion 
Protein  
SHR-1701 Phase 1 Jiangsu HengRui Medicine Bispecific Fusion Protein 
SAR439459  Phase 1 Sanofi Monoclonal Ab 
NIS793 Phase 1 Novartis Monoclonal Ab 
    
Small Molecule Inhibitors     
BMS-986416 Phase 1 Bristol-Meyers Squibb Small molecule, TGFβ1/TGFβ3  
Vactosertib Phase ½ MedPacto Small molecule, TGFβR1 
Galunisertib Phase 2 Eli Lilly and Company Small molecule, TGFβR1 
LY3200882 Phase 2 Eli Lilly and Company Small molecule, TGFβR1 
PF-06952229 Phase 2 Pfizer Small molecule, TGFβR1 
 
the use of vactosertib (TEW-7197) in combination with selumetinib (MEKi) in vitro and in vivo 
to disrupt stromal activation. Blockade of TGFβRI is hypothesized to target the stroma which acts 
as a TGFβ sink, given that TGFβ autocrine signaling was not observed in melanoma.  Disruption 
of TGFβ in this way would reduce melanoma EMT and plasticity that drives transition between 
mesenchymal and amoeboid invasion (Figure 28-2). Alternative strategies targeting TGFβ 
directly using small molecules or biologics such as TGFβR-ectodomain “traps” are currently the 
 79 
early phases of development (Table 2). However, non-specific targeting of TGFβ1/ TGFβ3 will 
be challenging for these therapies given the varied tissue-specific expression and contexts in which  
Individual TGFβ molecules signal. Conversely, targeted bispecific PD-L1-TGFβ fusion proteins 
hold promise to redirect progression while inducing an immunogenic response (Figure 28-4). 
However, these early phase clinical studies vs. monotherapy pembrolizumab are currently under 
investigation for non-small cell lung cancer (NSCLC) with high PD-L1 expression 
(NCT0331706). These bispecific approaches are reliant on the sensitivity of immune cells to home 
to tumors and detect differentially and sensitively detect anti-PD-L1 on tumors.  
This dissertation presents preliminary evidence showing that acquired resistance to 
vemurafenib (PLX4032) results in a drug-specific reduction in PD-L1 expression that correlates 
with treated cell lines and tumors (Figure 29A-B). Thus, bispecific therapies that exhibit efficacy 
in PD-L1 positive tumors may not lead to the destruction of proliferating resistant melanomas that 
PD-L1 negative and immunosilent. Therefore, there is virtue in utilizing either monoclonal TGFβR 
antibodies and/-or small molecule TGFβRI/II antagonists. Targeting the receptor as opposed to 
TGFβ would be expected to have reduced off-target cytotoxicity due to the fine-tuned intracellular 
regulation of TGFβRI/II-SMAD (Figure 28-4). Moreover, this dissertation has shown that CAFs 
respond rapidly to TGFβ1, suggesting that these cells readily express TGFβRI/II in comparison to 
uninflamed fibroblasts. However, strategies would benefit from the characterization of TGFβRI/II 
expression in CAFs and normal fibroblasts and cancers. Imaging combined with flow cytometric 
analysis of fixed cells could be used to experimentally determine the absolute number TGFβRI/II 
molecules during activation. Such data would help in elucidating the levels of TGFβ-TGFβRI/II 





Figure 28: Current and proposed strategies to target TGFβ and the TME 
The bioactive TME and drug stressed TME releases multiple cytokines to support tumor expansion and 
progression. (1.)  Stromal-derived transforming growth factor-β drives immunosuppressive CAF activation 
and T-regulatory cells while directly inhibiting CD8+ T-effector cells. (2.) Transforming growth factor-β 
also drives stress and apoptosis early in melanoma, while resistant clones respond by undergoing EMT, 
shifting between mesenchymal (left) and amoeboid (right), to escape immunosurveillance and form 
metastases. (3.) Pro-fibrotic TGFβ-activated CAFs synthesize ECM that captures TGFβ and excludes 
immune intravasation, while components such as TNC signal to innate-TLR4 receptors to drive M2-
protumorigenic activation. (LEFT) Therapies designed to suppress TGFβ and progression. (4.) 
Multiple immunotherapies and inhibitors of TGFβ/TGFβR are under investigation to halt the TME and 
drive immunostimulation. Both TGFβ/TGFβR monotherapies and bispecific TGFβ-checkpoint therapies 
are designed to shut down dysregulated TGFβ signaling and target cancers (melanoma) for adaptive 
destruction. 5. Blockade of TGFβ drives tumor regression through stalled production of fibrotic matrix 
allowing immune penetration and matrix remodeling. 6. Strategies to target CAFs for innate destruction 





Figure 29: Melanoma resistance to small molecules impacts immunotherpeutic targets 
(A) RNA-seq analysis to validate small molecule resistance in melanoma cell lines and xenograft tumors 
correlates with a reduction in PD-L1 expression (GSE64671). (B) Flow cytometry analysis shows a 
reduction in PD-L1 expression for vemurafenib (BRAFi, PLX4032) resistant A375 melanomas that is not 
observed for EGFRi (PD153035) resistant clones or parental lines. Data are displayed as geometric mean 
fluorescent intensity (n=3, technical replicates).  
 
findings such as the efficacy of atezolizumab (PD-L1 monotherapy), which was proportionately 
associated with TGFβ activity in the stroma (Mariathasan S et al., 2018).  
Regardless, neutralization of TGFβ signaling in the stroma in combination with 
immunotherapy or checkpoint inhibitors may prove less cytotoxic than inhibitors of TGFβR. 
However, our preliminary studies in mouse models show high tolerance no observable cytotoxicity 
for vactosertib (5mg/kg, ~5mM) in combination with MEK inhibition. This is of particular 
relevance given that vactosertib effectively blunted TGFβ-stress induction of stromal activation at 
1μM in cell culture (Figure 30). Interestingly, galunisertib (LY2157299) and anti-PD-1 have 
shown regression in engineered PDAC mouse models (Principe DR et al., 2019). However, 
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studies combining MEK and TGFβR inhibition are limited, and there are no current published 
studies or clinical trials for TGFβR inhibition in melanoma (Table 2). Therefore, this dissertation 
 
Figure 30: Animal tolerance to selumetinib and combination vactosertib therapies 
Animals bearing human metastatic melanoma xenografts were treated with control, MEK inhibitor 
Selumetinib (10mg/kg) alone or in combination with TGFβRi Vactosertib, TEW7197 (5mg/kg) for 4 weeks 
following a 7-day tumor establishment period. (n=4 animals per group). Data are presented as mean  s.e.m. 
 
 
is the first to test the effects of limiting TGFβ during the treatment and progression of melanoma. 
This dissertation proposes that the short-term stress responses in melanoma promote TGFβ-driven 
inflammation of CAFs, aberrant ECM remodeling, and progression to metastatic melanoma. Thus, 
this investigation dually concerned with eliminating tumor progression and in therapeutically 
preventing inflammation in the tumor stroma via suppression of TGFβ and tumor promoting ECM.  
  
 83 
Table 2: Clinical Trials Targeting TGFβ Activation in Cancer 




Interventions Acronym Conditions Results 
Not yet 
recruiting 
Phase I-II NCT04031872 LY3200882 EORTC1615 CRC NR 




































Withdrawn Phase I-II NCT03470350 Galunisertib EORTC1615 CRC NR 









Recruiting Phase I-II NCT03893695  GT90001+Nivolumab   MET HCC NR 
       
 
4.2 Overcoming tumor ECM and immunosuppression 
Future studies should investigate how CAFs are reprogramed in the presence of stress 
induced TGFβ. The coculture systems have been utilized to isolate RNA from normal and activated 
CAFs. Analysis of genes listed in appendix E in addition to cell-adhesion molecule arrays will 
provide beneficial insight into key ECM proteins that are activated in response to melanoma stress. 
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These proteins are presumed to look similar those that are expressed early in wound healing. Many 
of these proteins are associated with inflammation, or fibrosis if chronically expressed. 
Experimental evidence of this has been established in lung adenocarcinoma, wherein human 
tissues were proteomically profiled. The authors found that TNC was upregulated in fibrosis and 
metastasis (Gocheva V et al., 2017).  
Another study implicated chemotherapy induced stress in breast cancer as an activator of 
c-Jun (JNK) which lead to TNC and SPP1 activation. Inhibition of c-JUN (JNK) with JNK 
inhibitors abrogated these ECM molecules and restored sensitivity to chemotherapy (Insua-
Rodríguez J et al., 2018). Pathologically inflamed ECM is paradoxically linked to TGFβ signaling 
in fibroblasts, which are postulated to create collagen rich peri-tumor stroma that prevents both 
drug and immune cell penetration (Figure 28-3). This dissertation identified the colocalization of 
αSMA stroma flanking TNC rich micrometastatic melanoma nodules in the livers of xenografted 
animals. Future studies would benefit from additional staining of tumor sections to correlate 
collagen expression with CD68 macrophage and CD8+ infiltrate in untreated and treated groups. 
The TGFβ shaped ECM fortress surrounding metastatic urothelial cancer has been credited with 
preventing T-cell infiltration and subsequent failure of PD-L1 atezolizumab. This occurred in spite 
of evidence pointing to inflamed melanomas are most responsive to checkpoint blockade (Tumeh 
PC et al., 2014). Combined check point inhibition and TGFβ blocking antibodies suppressed CAF 
signaling and resulted in intra-tumoral T-cell penetration and tumor regression (Mariathasan S et 
al. 2018). A similar outcome in mouse models of metastatic CRC found that stromal TGFβ limited 
T-cell and differentiation of effector TH1 cells. However, targeting TGFβR1 with galunisertib 
ablated the immunosuppressive stroma, and enabled PDL1+ immune infiltration into established 
liver metastases and restored anti-PDL1 ICD (Tauriello DVF et al., 2018) (Figure 28-5).  
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Prompted by this, we established an in vivo study examining the effects of combined 
inhibition of MEK in patient 12-293 metastatic melanoma and vactosertib mediated suppression 
of TGFβRI/ALK4/5 to suppress therapy induced CAF activation. Preliminary evidence from this 
study showed inhibition of metastases to the liver and objectively reduced burden to the spleen 
injection site. Thus, future studies will focus on examining tumor reduction and cell death with 
respect to the ECM and αSMA stroma. Particular focus should be given to TNC, where this 
molecule is expressed (intratumorally vs. invasive edge), and whether DCN exhibits mutually 
exclusive expression.   
Tenascin-C is also highly expressed in metastatic melanoma and is seemingly an attractive 
signature or target (Figure 28-6, Table 3). However, there is uncertainty regarding where the TNC 
epitope of Iodine (I) I-131-monoclonal 816C antibody is expressed in tissues. Therefore, this 
antibody does pose toxicity issues if it were to bind TNC in non-involved or fibrotic tissues. In 
these non-specific sites, this antibody could potentially activate or exacerbate pre-existing 
inflammation. However, there may be opportunity to exploit these antibodies as bispecific(s) with 
EGFR or PD-LI, or TGFβR moieties. However, designing these may be challenging. Thus, 
immediate head-to-head tests comparing mono-vs.-combination therapies cetuximab (anti-EGFR) 
and anti-EGFL TNC antibodies could prove useful in metastatic melanoma. These approaches 
could be elaborated by inclusion of TGFβI/II small molecule inhibitors or therapeutic antibodies. 
This work is pivotal as there is currently no evidence on whether antibody dependent cell-mediated 
cytotoxicity (ADCC) drives cell-stress. However, targeting TNC will remain challenging 
nonetheless, as all trials were stopped at Phase II with not reported results. Therefore, the best 
strategy is likely one that suppresses inflammatory ECM molecules through the suppression of the 
CAFs, which are the source.  
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This dissertation aims to expand the known repertoire of ECM molecules that are 
differentially expressed in response to melanoma TGFβ and how this transcriptional landscape is 
changed during combined MEK/TGFβR in vitro inhibition. Our preliminary data shows that this 
is well tolerated and effective at preventing metastasis in mouse models. However, there may be 
additional opportunities to reinvigorate the use of TNC targeted monotherapies, by combining 
these epitopes with antibodies against fibroblast associated protein (FAP). Combined targeting in 
this manner is expected to prove more efficacious in the treatment and destruction of CAFs. This 
therapy may even have hitherto unappreciated use in treating TNC positive fibrotic diseases. 
Beyond these conventional approaches, TNC monotherapies could also be used in the generation 
of neo-antigens for use in chimeric antigen receptor (CAR) T-cell therapies. There already exists 
CAR-FAP T-cells that have been efficacious in the treatment of cancers. Moreover, circulating T-
cells with antigens for early response proteins such as TNC which are vital to establishing 
micrometastases disease, may prove highly useful in the management of metastatic melanoma, 
both in limiting residual disease and by abscopal effect. However, the studies presented in this 
section would be foundational for any future approaches regarding bispecific targeting or T cell-
based therapy. Ultimately, there is great promise in limiting the inflammation of the TME while 







Table 3: Clinical Trials Targeting TNC Activation in Cancer 




Interventions Acronym Conditions Results 








Neuradiab + Radiation + 
Temozolomide 
Glass-Art GBM NR 
Completed Phase I NCT00002753 
Radiation+I-131 Mab 
81C6  












Surgery+ I-131 Mab 
81C6 
  Brain/CNS NR 
Completed Phase I NCT00003484 
Carmustine+Radiation+I-
131 Mab 81C6 




























Appendix A – The great escape: how metastases or melanoma, and other carcinomas, avoid 
elimination. 
Text from this chapter appears in Experimental Biology and Medicine (Maywood). 2019. 243; 17-




Cancer mortality ensues from metastatic growths. Cancers use two strategies to allow for 
this unrelenting expansion. The first way is that early metastases are often cryptic or dormant, 
being invisible to both innate suppressive actions and undetected clinically.  Second, both the 
micrometastases and later clinically lethal growths are resistant to therapies, whether standard 
chemotherapies, targeted biologics, or even immunotherapies. These two modes of resistance 
necessitate new approaches to treatments if we are to eliminate mortality from solid tumors. 
However, to develop such therapeutic strategies, we first need to better understand the cellular 
behaviors and molecular events that enable the resistances. Herein, we present a comprehensive 
model of changing methods of avoidance and resistance that occur during tumor progression, and 
doubly confound treatment by mixing survival strategies throughout the continuum creating 
moving targets. Melanoma is presented as the model cancer, as it is being targeted by all three 




Appendix A.1 Introduction 
Metastatic progression of solid tumors is the harbinger of most morbidity and mortality 
from solid tumors. The initial primary tumor growth is most always capable of being eliminated 
by surgical excision or radiological ablation. While this may lead to real morbidity from the 
surgery and its sequelae, and the unusual death, the outcomes are increasingly curative as we 
appear to catch many at their earliest stages. Over 80% of melanomas and breast and prostate 
cancers are eliminated in this manner. However, if the tumor has already disseminated, the long-
term outlook becomes bleaker with five-and-ten year survivals falling dramatically; for melanoma, 
fewer than a third of patients survive past a half-dozen years.  
The issues that confront the survivors of the primary lesions are that the metastases are not 
only not amenable to removal, due to wide dissemination, but also that these cancer cells are 
generally more resistant to cancer-targeting agents. This is seen most clearly with neo-adjuvant 
breast cancer treatments that will shrink the breast nodule, even leading to a complete pathological 
response (no cancer cells detectable) upon subsequent lumpectomy, while not significantly 
impacting the overall survival (1-3). At least a subset of the disseminated cells presents distinct 
properties from the primary tumor cells in terms of therapeutic responsiveness. As this is seen even 
with therapy naïve cancers, it is unlikely that this is due to genetic mutations, but rather is micro-
environmentally imprinted on these cells in ectopic sites.  
To overcome such resistance to therapy, we need to understand the phenotypic and cellular 
changes that cells undergo during progression. Initial studies have begun to dissect such switches 
and decipher their impacts on therapeutic responsiveness. Herein, we propose a unified model for 
tumor progression linking the micro-environmental induction of phenotypic switches with 
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susceptibility to therapeutic approaches. This provides for testable hypotheses and pathways to re-
sensitize disseminated tumor cells to accepted therapies. 
 
Appendix A.2 The Metastatic Cascade 
Dissemination from the primary site relies on the ability of tumor cells to survive and grow 
in a metastatic site and requires many changes to adapt to the tissue-specific environment unique 
to each organ (4). Tumor metastasis, even more than carcinogenesis, involves both the carcinoma 
cell and the host environment (Figure 1). Dissemination most likely requires distinct cancer 
phenotypic switching. Initially, a cancer-associated epithelial-mesenchymal transition-like 
plasticity (cEMT) allows for the autocrine signaling and loss of cell-cell constraints that promotes 
escape from the primary site (5, 6). It should be noted that in referring to cells as epithelial or 
mesenchymal, we are denoting the presence or absence of cell surface E-cadherin, loss of cell-cell 
cohesion, and shape shift towards fibroblastoid without epithelial cell polarity; this is not a true 
phenotypic switch at the full transcriptome level (7). This phenotypic plasticity, in part driven by 
the now-enabled autocrine growth factor signaling through the EGF receptor (8, 9) and 
downstream involving the Met receptor for HGF (10). This is further augmented by signaling from 
an altered localized micro-environment, both the matrix and the cells. This resembles a wound 
environment, with activated fibroblasts (CAF, cancer-associated fibroblasts) and an immature 





Figure 31: Metastatic Cascade to Liver 
Schematic of metastasis with postulated phenotypes that confer resistance or sensitivity to therapies. 
Disseminating carcinoma cells must acquire mesenchymal-like migratory properties to escape the primary 
locale (the cEMT). Transit through vascular conduits to sites of metastasis are fraught with challenges with 
most tumor cells not surviving but are sufficiently transient to not represent a target for therapy. At the 
metastatic site, cells must survive apoptotic cytokines initially and chemotherapy later; this is accomplished 
by a reversion to a more epithelial phenotype and expression of E-cadherin (cMErT) that in turn provides 
for the chemoresistance and immune silence [PD-L1-negative], driven at least in part by host organ 
extracellular vesicles (Green bubbles). Cells emerge from dormancy due to inflammatory stimuli (lightning 
bolts) to form aggressive, lethal metastatic nodules with re-acquisition of mesenchymal-like behaviors and 
cause the organ to secrete factors with secondary metastases also ensuing. (adapted from (58)). 
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but also to attract immune cells that further promote invasion and dissemination (15, 16). The 
combination of a mesenchymal, highly motile and physically plastic cancer cells with a disrupted 
pliant matrix allows for invasion through these barriers, whether the limiting basement membranes 
and outer muscular capsules in carcinomas or the thicker dermis in melanomas.  
After transiting these barriers, the cancer cells must survive travel in a flowing conduit to 
metastasize. Whether the intravasation occurs in the hematogenous or lymph vasculature, the final 
extravasation is occurs from the hematogenous capillary bed (lymph node seeding is a separate 
category of dissemination from ectopic organ metastasis). While the processes of this transit and 
survival in a turbulent flow are complex, this short event is neither a reservoir of tumor cells nor 
an opportunity for treatment and will not be discussed further.  
At the other end of dissemination, the greatest challenge for metastatic seeding is 
integration into the ectopic metastatic tumor microenvironment despite the lack of a supportive 
environment and presence of pro-death signals from a local inflammatory response. Interestingly, 
metastases of breast and other carcinomas often express E-cadherin (9, 17-19), whose initial loss 
is the hallmark of cEMT and correlates strongly with dissemination (20), even if expression of 
mesenchymal markers are absent (21). This reversion to an epithelial phenotype is secondary to 
loss of mechanisms that suppress E-cadherin expression such as loss of promoter methylation (17) 
and Kaiso binding to the promoter (22-24), and abrogation of EGF receptor signaling that 
downregulates E-cadherin (8). We have reported that carcinomas and melanomas re-express E-
cadherin in metastatic tissues such as liver, lung and brain (7), while others have reported such in 
bone marrow metastases (18, 19, 25), but not in lymph nodes (data not shown). Other epithelial 
markers including connexins are similarly upregulated in the metastatic niche (20). This reversion 
of cEMT or a cancer-associated mesenchymal-epithelial (reverting) transition (cMErT) is only 
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partial to the same extent as the initial cEMT is also partial (7), suggesting a metastable or plastic 
situation that allows for outgrowth upon a second cEMT (6).  
A portion of these disseminated cells can enter a period of dormancy to later emerge as 
aggressive metastatic tumors. This ‘dormancy’ may be quite transient, as in the case of triple 
negative breast cancers, or extended as in hormone receptor-positive breast cancers (even in excess 
of two decades before clinically evident recurrence). However, evidence is accumulating that 
epithelial reversion is a feature of dissemination for most all carcinomas and likely melanomas. 
The mechanisms underlying dormancy are poorly understood as successful metastatic seeding and 
dormancy (as opposed to primary escape and dissemination (26)) are rare events (27, 28). This gap 
in our understanding is due in large part to the absence of tractable experimental systems that can 
focus on this stage to metastasis, a limitation we will discuss later. Successful ectopic seeding with 
its epithelial reversion appears to be linked with entry into dormancy. The tumor signals that enable 
intercalation within a tissue (including extracellular vesicles [EV]) (29-32) leads to reverse 
signaling (including EV) from the receptive organ that imparts the cMErT and initial dormancy 
(33, 34). 
The state of the tumor cell in dormancy is unknown, with one model positing quiescence 
versus another of balanced proliferation and death. In silico modeling determined that it is highly 
unlikely that micrometastases exist in a state of balanced proliferation and death, but rather either 
grow out or enter quiescence (35, 36). The quiescent dormancy model is supported by findings of 
suppressive matricellular proteins in the pre-metastatic niche coinciding with failure to establish 
macrometastases (33, 37). As will be discussed, whether the cells are cycling or quiescent during 
dormancy would affect their ability to be targeted by cycling-dependent agents such as those 
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disrupting DNA replication or intermediary signaling pathways for mitogenesis (such as raf and 
MEK inhibitors in use for melanomas).   
This also raises the questions of what signals keep the cells in quiescence, and which 
‘awaken’ these dormant metastases. It appears that the (re-)expression of E-cadherin coincides 
with entering dormancy (7, 17), but does not dictate quiescence as cells expressing surface E-
cadherin demonstrate mitogenesis particularly notable in the early stages of melanoma- and 
carcinoma-genesis. Importantly, this emergence from dormancy occurs along with a second cEMT 
shift (7, 38). Initial studies suggest that stressors of the microenvironment, whether inflammatory 
cytokines or immune activators, can induce cEMT even in well-differentiated carcinoma cells (39-
42). This is supported by our finding that stressed endothelial cells activated a emergent or 
mesenchymal phenotypic shift in an E-cadherin-expressing breast carcinoma cell line via secreted 
growth factor (39), and work by others implicating a role for endothelium undergoing sprouting 
as driving tumor emergence (33). Additional signals can derive from activated stellate cells and 
macrophages to promote this same shift (40, 41). Interestingly, using an ex vivo model for 
dormancy and emergence, we have reported that outgrowth is reflected in a globally inflamed 
organ (as denoted by increased levels of cytokines, chemokines and growth factors) while 
dormancy occurs in the setting of an organ that is ‘quieter’ than normal homeostasis (43, 44). This 
evidence that emergence results from, or at least along with, chronic inflammatory activity, along 
with recruitment of immune cells should have implications for the sensitivity of such emergent 




Appendix A.3 Investigative Models 
The study of therapeutic resistance is hindered by model systems that truly reflect either 
the development of metastases or the treatment of such in humans. Examination of patient 
specimens is capable of capturing the heterogeneity both between and within patients but suffers 
from a number of limitations. The mains ones are (a) static sampling and thus not open to 
determining cancer plasticity, (b) inability to evaluate the earliest stages which are undetectable, 
(c) interventions limited to singular regimens, and (d) selection bias. To overcome these, a number 
of models have been developed to isolate specific aspects of metastasis and therapy, each with 
their own benefits and limitations.  
Appendix A.4 ‘Spontaneous’ rodent metastasis  
There are a number of variations of these models. The basic concept involves tumors that 
develop in mice usually due to genetic engineering to express a specific oncogene in the target 
tissue; examples include the V600E melanoma (45) and various hormone-driven oncogenes in 
breast cancer (46, 47) or prostate cancer (48, 49). Chemically induced tumors include those of the 
liver and other organs. In a few cases, the tumor has developed spontaneously in a particular strain, 
such as the B16 melanoma, and then is re-introduced into syngeneic animals. For the genetically 
engineered models, the tumor biology follows from the specific mutations made, and thus only 
reflects a subset of patients. 
These whole animal models benefit from being in intact (i.e. immunocompetent) animals 
and capturing carcinogenesis and progression. The endogenous nature, or syngeneic aspect when 
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transplanted, allows for a complete immune system response, including acquired immunity, even 
if the murine immune systems is not directly replicative of the human situation. A major limitation 
is that these tumors often do not metastasize at high frequency or predictably. This may be 
overcome by isolating tumor cells from metastatic target organs and re-introducing them 
orthotopically with serial enrichment yielding more pliant models.  
Appendix A.5 ‘Inoculated’ rodent models 
Rodents are used as the hosts of transplanted tumor cells for two reasons in metastasis 
research. In the first, it is to directly inoculate tumors into ectopic tissues, providing for grafting 
of tumor cells in organs of metastasis; this is most often published as injection into the tail vein to 
obtain tumors in lungs, and into the left ventricle to obtain tumor cells disseminated widely with a 
high predilection to bone. In the second aspect, it is to seed human tumors to study the 
heterogeneity of human specimens or the de novo nature of carcinogenesis unique to humans; 
these tumor xenografts can be from cell lines or directed human specimens (PDX) either 
orthotopically or ectopically. Of course, these two aspects are not exclusive, with human tumor 
cells often being targeted directly to metastatic organs. 
The advantage of the direct inoculation into ectopic organs is that the tumor reaches the 
ectopic tissue at predictable rate and time, enabling tracking of specific stages of metastases. This 
has been used to study both longer term outgrowth and treatment and even the initial minutes to 
hours of seeding. In a seminal study, B16 melanoma cells were introduced via the portal vein into 
the liver to track their fate over the ensuing hours to days to weeks; this demonstrated a high rate 
of extravasation but <1% long-term outgrowth rate even for this clonally-selected highly 
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aggressive tumor (27). Such approaches have been extended to metastatic seeding in the brain 
(28).  
Despite these advantages, this ‘directed metastasis’ approach opens the question to whether 
the normal pathological processes are overwhelmed and thus the results are skewed. While the 
very low efficiency, often on the order of 0.1% of inoculated cells resulting in macrometastases, 
reflects the likely human situation, the rapid appearance of the macrometastases belies the clinical 
experience wherein even ‘rapid’ recurrences require months to years before reaching similar sizes. 
It is quite likely that the large bolus of extravasating cells overwhelms the pathophysiological 
responses that drive the epithelial reversion and dormancy noted when limiting numbers of cells 
are introduced. The quantitative nature of this balance is noted in tumor cells producing greater 
numbers of EV than the host parenchymal cells, but with this being counterbalanced by the 
numerically vaster numbers of host cells upon single cell seeding (34). Similarly, the growth 
factor-rich milieu of tumor cells may also overwhelm the death signals from the innate immune 
response to foreign bodies/cells, enabling greater survival of mesenchymal aggressive tumors. This 
is important in studying resistance to therapy if the surviving and outgrowing ‘metastatic’ tumor 
cells have not upregulated key molecules and behaviors that normally function to enable metastatic 
seeding, and thus would appear as falsely sensitive growths. 
Spontaneous metastases from orthotopically placed tumors avoids this ‘bolus’ effect. The 
resulting metastases undergo the patho-physiologically relevant phenotypic switches and more 
likely reflect clinical situation (50). For syngeneic rodent tumors, this includes the input from the 
innate and acquired immune systems (and subsequently allows for examining immune-modulating 
therapies), but still suffers from the limited diversity of rodent tumors and translatable 
discrepancies to the human immune system. For human xenografts, this captures the clinical 
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heterogeneity and can parse out those cells that have metastatic capacity. However, the immune-
deficient hosts that are required obviate the input from any acquired immune system inputs or the 
assessment of such tumor vaccines or lymphocyte-mediated immunotherapy (the immunologic 
competence or completeness of ‘humanized’ mice hosts is still uncertain and usually does not 
match the transplanted immune system with the particularly tumor cells). Even the innate immune 
response may be limited in these hosts, though the nu/nu mouse system appears more robust and 
replete than the more facile NOD SCID mice (51). The involvement of the immune system inputs 
in metastasis and therapy are open to question as there are subtle but important differences between 
rodents and humans; for melanoma in particular this is amplified by the overwhelming 
predominance of gamma-delta T cells in the skin site of melanoma-genesis and invasion, versus 
the human situation in which the adaptive alpha-beta T cells are the vast majority in these locales 
(52). 
Appendix A.6 Ex vivo models of metastasis 
Ex vivo organotypic models can provide an all-human context as the human 
microenvironment has species-specific signaling, and many of the newer biologic and 
immunologic therapies are optimized to work with human sequences. Equally important, this 
approach can allow for near continuous assessment of the metastatic cascade, with repeated 
imaging of the same micrometastasis. Sacrificing the entire animal model for a more limited organ 
tissue allows for such analyses. The details of these different models vary but certain limitations 
are shared including (a) lack of input (soluble and vesicular signals and hormones) from other 
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tissues, (b) limited immune system presence and functioning, and (c) time-span limitations of days 
to weeks.  
The simplest replete models are tissue slices, most often of brain or liver, onto which tumor 
cells can be directly seeded. These allow for limiting the number of cells to reflect the clinical 
situation and following multiple individual events. As brain and liver are two common organs for 
metastases and are often the ones of worst prognosis, the clinical relevance of attacking these 
micrometastases is obvious. Two other commonly involved organs, lung and bone marrow, do not 
lend themselves to tissue slices due to the physical nature of air/tissue and bone/marrow interfaces, 
respectively. Compromising the utility of these models is the lack of fluid flow through the tissue 
that leads to hypoxia and buildup of toxic metabolites that limits the functionality to days.  
Recent developments in microphysiological systems (MPS) provide the opportunity to 
overcome some of these challenges. MPS are complex tissue constructs, generated from individual 
components (rather than fragments of human tissues), and maintained under engineered conditions 
that provide for continuous circulation of media, to avoid static conditions that plaque the tissue 
slices. The cells are either primary human, or more often for ease and reproducibility non-
transformed cell lines or differentiated iPSC. The former can be highly limited (except for skin 
cells), while the latter two groups are not fully mature, functional and differentiated. On a positive 
note, the media flow can be regulated to deliver nutrients and therapeutic agents in a manner 
reflecting the human physiology or the pharmacokinetics of drugs. This enables these constructs 
to function for over a month, a period sufficiently extended to study by drug efficacy and 
resistance, and secondary challenges (43, 44).  
Again here, the most advanced of these MPS are skin, neuropile/brain and liver. While the 
skin organ cultures have been used to study melanoma invasion (53, 54), the greater potential for 
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examining the behavior of tumor metastasis lie in the target organs. As these MPSs are nascent, 
there are few studies investigating metastatic behavior, though even these have led to new insights. 
It was with an early liver MPS that the tight junctions that metastatic carcinomas can form with 
parenchymal cells were first reported (55), and that the epithelial reversion was dissected (17, 34, 
56). The construction of the current MPS and the complete complement of parenchymal and 
nonparenchymal cells (including immune cells) is described elsewhere (57, 58). These studies in 
the liver MPS have recently been used to examine the role of inflammation in driving emergence 
from dormancy (40, 43, 44), with findings reflecting those suggested by clinical experience and 
animal models (33, 37).  
Appendix A.7 Resistant to therapy 
The greatest challenge to treating metastases is that these appear to be inherently harder to 
kill or control than the primary tumors from which they arise. This is not often able to be 
determined directly, as primary tumors are mostly found prior to clinically evident metastases and 
removed. However, in clinical situations where tumors are treated along with synchronous 
metastases or as neoadjuvant prior to removal, it appears that the disseminated cells are less 
responsive. A large, early meta-analysis of neo-adjuvant therapy for breast cancer found no 
increase in overall survival despite strong responsiveness of primary cancers (1). Even when both 
the breast primary and positive lymph node nodule respond the adjuvant systemic chemotherapy 
with complete pathological remission, the cure rate is far less than complete (3). These insights 
suggest a survival advantage for the disseminated cancer cells. Herein, we will provide a model, 
based on preclinical studies of micrometastases to account for this resistance to therapy. 
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This discussion will focus on generalized resistance to therapies. This is distinct from 
selective resistance that often appears in the surviving cells after a particular agent is used and is 
usually accompanied by a genetic change that may confer survival; this is often selected in 
preclinical models by repeated exposure to subtotal death challenges. A long-standing well 
documented situation is the genetic amplification of DHFR (dihydrofolate reductase) to escape 
killing by methotrexate; a property exploited in genetic engineering of cells. Other situations 
include target molecule point mutations to render them impervious to the agent (tubulin mutations 
to render taxanes ineffective), upregulation of P-glycoprotein/MDR1 drug efflux pumps (for many 
chemotherapies such as doxorubicin), loss of the molecular target of the agent (one example is 
HER2, accompanied by upregulation of related oncogenes), and second molecule mutations to 
compensate (this is the mechanism for vemurafenib resistance by commensurable NRAS 
mutation). While overcoming such specific survival mechanisms are presumed to be critical, the 
combination approach to most disseminated cancers make these individual changes less likely. 
The latter points to either a non-genetic adaptation or a protective effect in the disseminated cells, 
which is the aspect that will be proposed herein. 
It has become accepted that the microenvironment contributes to the generalized chemo- 
and immuno-resistance of metastases (59-62). While much work has focused on specific cancer 
cell intrinsic mechanisms for resistance to individual agents as noted above, the issue confronting 
our patients is generalized therapeutic failure. This pan-resistance appears to be due to trophic 
factors and signals from the micro-environment (61, 63-67) that drive changes in the cancer cells 
and the microenvironment itself (68). What remains unclear is if a particular tumor is protected by 
specific factors (e.g. TGFβ production or collagen-mediated suppression), or if there is a 
progression wherein during the early stages of seeding E-cadherin-mediated signaling comes to 
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the fore while larger emerging metastases drive stromal reactivity to provide protective factors 
such as tenascin C (14, 54, 69). As there is little evidence of trophic changes in the earliest single 
or few cell stage and the carcinoma cell phenotype is plastic (6), we posit that the 
microenvironment and the cancer changes in response to this drive different levels of therapy 
resistance at each stage of progression (Appendix A - Figures 2-4). 
 
Figure 32: Mechanisms of therapeutic resistance in the primary tumor 
i) Escape from the primary tumor site is promoted by the tumor microenvironment being altered with 
upregulation of motility-promoting matricellular and matrix-associated proteins (e.g. TNC). TNC is at the 
invasive front as demonstrated in ii) an invading melanoma cell lines, and iii) a patient melanoma 
specimen (adapted from (54)). However, as these cells are highly active, these protections from death are 
minimal in the pre-disseminated site. 
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Appendix A.8 (Limited) Resistance in the primary site  
The primary tumor site is often the most sensitive to therapies (Appendix A – Figure 2), 
though the usual approach is to remove surgically, particularly for melanoma, or radiologically in 
some internal carcinomas. However, in some cancers, neoadjuvant therapy is being used prior to 
surgical removal. These clinical experiences have shown remarkable responses in primary breast 
cancers shrinking and disappearing (1, 3) even though the impact on overall survival is small to 
non-existent. Furthermore, clinical experience with carcinomas with synchronous metastases (and 
therefore often not surgically resected) often shows a differential responsiveness, as hinted at by 
the dichotomy of complete pathological response of primary breast cancers to neoadjuvant therapy 
with limited impact on clinically undetected metastases that drive the overall survival rates. This 
is noted with both chemotherapies in which metastases persist through treatment (70), and even 
killing by cells of the innate or acquired immune system (71, 72).  
Still, a fraction of the invasive tumor cells is capable of surviving lessened cohesion to cells 
(and the survival signals from those connections) and transit through an ectopic 
environment/barrier, the dermis for melanoma. While much of the invasiveness appears to be 
syncytial, bringing the orthotopic support systems, amoeboid motility of the melanomas allows for 
separation at the front. In breast cancer it has been noted in experimental systems that 
disseminating cells break from the nodule to migrate and intravasate separately (73). Both the 
escape and survival during the process are promoted by the tumor microenvironment being altered 
with upregulation of matricellular and matrix-associated proteins normally present during wound 
healing (53, 69). Not only do these proteins promote migration and invasion, but also impart 
survival advantages (74, 75). However, as these proteins are limited to the leading edge of these 
invading tumors (54), the protection is likely limited.  
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Appendix A.9 Avoidance of the micrometastases 
Successful seeding of the ectopic site, with less than 1% of the cells that reach to target 
organ, is the most rate-limiting step in the metastatic cascade (27, 28). Thus, the survival 
mechanisms are either present in a small fraction of the disseminated cells, or only a limiting 
number of even clonal cancer cells can undergo changes sufficiently rapidly to survive. We posit 
that this involves the phenotypic switch that is linked to dormancy (6) (Appendix A – Figure 3). 
Disseminated tumor cells face a hostile microenvironment in which the orthotopic matrix 
and cell composition is lacking, and thus the cell is absent the trophic factors that sustain 
homeostasis in the original tissue. Cells can overcome this in a number of ways. First, they can 
produce some of the factors themselves, such as secretion of tenascin C by melanomas (14, 53) 
and other cancers. In addition, signals from the metastasizing cancer cells alters the host 
environment to produce some of these ‘wound’ matrix components (34, 76). A second mode is to 
switch to a low metabolic state by entering quiescent dormancy; this requires a reversal of the 
autocrine growth factor signaling that characterizes the initial cEMT and drives proliferation (8, 
20). Thus, the successful micrometastases avoid the starvation of loss of trophic factors. 
Another challenge is the nonspecific inflammation triggered locally by intravasation and 
intercalation of the tumor cell into the ectopic parenchyma. This releases both soluble and cellular 
challenges. Part of the escape from the cellular attack is for the metastatic cells to be 
immunologically invisible. There is mounting evidence that PD-L1, which imparts aggressiveness 
to cancer, is downregulated in successful micrometastases of prostate and breast carcinomas (77, 
78), and likely also in melanomas (79). Interestingly, this immune escape may be linked to the 
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cMErT via limited maturation of PD-L1; EGF receptor signaling drives N-glycosylation needed 
for cell surface presentation of PD-L1 (80), but during cMErT EGFR signaling is limited (8).  
Worse than immune-escape, is the situation of paradoxical response of aggressive 
outgrowth in response to immunotherapies, a situation seen in up to one quarter of patients and 
termed hyper-progressive disease (81). A recent clinical report has described a cohort of 406 
patients having advanced non-small cell lung cancer and treated with PD-1/PD-L1 inhibitors in  
which 13.8% experienced hyper-progressive disease which was correlated with a significant 
overall worse survival (3.4 vs. 6.2 months) (82). This situation has also been noted anecdotally in 
melanoma (83). While the  mechanism of this hyper-progressive response to presumed anticancer 
agents remains unclear,  the proposed model  suggests a number of testable hypotheses that are 
concordant with an initial suggestion that activation of the microenvironmental tumor associated 
macrophages contribute to this perverse outcome (84). This would represent yet another 
mechanism for escape from treatments. 
Successful seeding also likely requires acquisition of positive signals and not just limiting 
damage. This is likely provided by the E-cadherin signaling upon heterocellular ligandation after 
cMErT (20). E-cadherin ligandation leads to a low level tonic activation of the canonical survival 
signaling pathways through MEK-ERK and PI3-kinase-AKT (85), providing for possible survival 
signaling. We have reported that such mechanisms provide chemoresistance in breast and prostate 
carcinoma (68). This protection functions not only in vitro but also in vivo wherein inhibitors that 
are not individually effective in limiting or killing metastases re-sensitize the E-cadherin-positive 
dormant micrometastases to killing by chemotherapies (86). Thus, the disruption of either of these 
 107 
survival signal cascades brings the response of the dormant metastases to be similar to that of the 
mesenchymal aggressive and chemosensitive primary metastases.  
 
Figure 33: Mechanisms of therapeutic resistance in the micrometastases 
Micrometastases escape therapy by up-regulation of survival and down-regulation of target molecules. ii) 
Tumor cells expressing high levels of the E-cadherin in the liver are more resistant to chemotherapy than 
those expressing low levels (adapted from (86)). iii) An inverse relationship between E-cadherin 
(chemoresistant) and PD-L1 proteins (here shown in experimental metastasis models in the mouse, 
unpublished data) would obviate immunotherapy targeting. iv) EVs from the organ tissue of the metastatic 
site, particularly the non-parenchymal immune and stromal cells, drive the conversion cMErT in colonizing 




Appendix A.10 Resistance of the macrometasteses 
The resistance of dormant micrometastases would be less problematic if the emergent 
macrometastases were responsive to therapeutic agents. As the lethal outgrowths present a 
mesenchymal phenotype, having undergone a second cEMT, often re-expressing PD-L1, these 
should be responsive to chemo- and immuno-therapy. Clinical experience suggests that such 
outgrowths may be in part responsive, as often these shrink or even disappear upon exposure to 
various chemo-, biologically-targeted- and immuno-therapies (Appendix A - Figure 4). However, 
these systemic treatments are usually not curative. The almost inevitable recurrence may come 
from cryptic dormant micrometastases that have avoided therapeutic effects, or from a subset of 
emergent mesenchymal cells that are protected from killing. If the former, then one would expect 
the recurrences to display the same sensitivities as the original metastatic growths, whereas if these 
recurrences derive from surviving cells, a pan- or acquired- resistance should be noted. The 
localization of the recurrences would not shed light on either of the mechanisms, as even 
outgrowing macrometastases may harbor dormant nests, and emergent metastases may 
disseminate and seed secondary sites without undergoing dormancy (4, 87).  Clinically, both 
situations are seen upon treating the recurrences, but most often the resistance profiles are different 
than the original metastasis (88), suggesting that the latter situation of an adaptive or selected 
population persisting.  
The growing metastasis appears as undifferentiated and mesenchymal, with reduced to 
absent E-cadherin (7). Such cycling and metabolically active cells should be as susceptible to 
therapies as the primary lesion; however, this is not the case, and not simply due to exposure-
related selection or mutation. The reason for this relative resistance may be that trophic factors in 
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the metastatic niche are providing survival signals. A candidate for this would be the matricellular 
protein tenascin C which is present throughout the metastatic bed of melanomas (Figure 11) and 
Figure 34: Mechanisms of therapeutic resistance in the macrometastases 
i) Mechanisms of therapeutic resistance persists through a second cEMT and subsequent overt 
growth. ii) Therapeutic resistance of tumor cells is maintained via the production of the same 
matricellular and matrix-associated proteins (e.g., TNC) produced during the first cEMT event for 
invasion with this now encasing the entire metastasis. iii) E-cadherin expression inversely 
correlates with tumor size, with the loss of E-cadherin tracking with emergence as a clinically 
evident metastatic nodule, opening the way for greater therapeutic sensitivity (adapted from (7)).  
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other carcinomas (11, 54). Again here, the ultra-low affinity/high avidity EGF-like repeat 
interaction with the EGFR on the melanoma cell would provide for survival signals. This should 
be more effective than during initial invasion as the metastases appear to be encased in such a 
matrix. 
Appendix A.11 Commentary 
Metastases challenge our ability to cure or ameliorate the cancer due not only to the 
geographically widespread and often inaccessible nature, but also because they are inherently more 
resistant to systemic treatments than the primary growth. This escape from elimination is 
accomplished mainly through non-mutational events based on the plasticity of the tumor cells. The 
changes in cellular behaviors and phenotypes, shorthanded as epithelial or mesenchymal based on 
shape and E-cadherin cell surface presentation or lack thereof, respectively, are imparted in large 
part by the dynamic micro-environments that the melanoma or carcinoma cells progress through. 
As part of these switches, the successful cells are provided with attributes or signals that provide 
protection from endogenous killing by the innate inflammation of tumor progression or exogenous 
toxins of therapies. The survival advantage is greatest in the dormant micrometastases that are not 
only clinically invisible but avoid detection by the immune system, and whose linked quiescence 
and E-cadherin-triggered survival signals protect against chemo- and targeted-therapies. 
Protection persists even after active emergence and growth, though to a seemingly lesser extent, 
again due to changes in the matrix of the metastases, including expression of matricellular protein 
tenascin C. 
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This model accounts for the changes in sensitivity to treatments through progression. However, 
many of these steps have not been demonstrated in vivo. The main issue is whether 
macrometastases recur after treatment due to encompassed dormant nests or from adaptation of a 
portion of the macrometastases. The basis has immediate implications for developing new 
approaches to treat these resistant growths. If it is from adaptive changes, then this needs to be 
accounted, versus the outgrowth of quiescent dormant cells, in which case the challenge is to 
prevent these cells from being awakened, or resensitizing the dormant cells. If this can be 
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Appendix B - Mesenchymal stem cell/multipotent stromal cell augmentation of wound 
healing: lessons from the physiology of matrix and hypoxia support. 
Text from this chapter appears in American Journal of Pathology as a review on stem cells and 




Cutaneous wounds requiring tissue replacement are often challenging to treat and result in 
substantial economic burden. Many of the challenges inherent to therapy mediated healing are due 
to comorbidities of disease and aging that render many wounds as chronic or non-healing. 
Repeated failure to resolve chronic wounds compromises the reserve or functioning of localized 
reparative cells, particularly in wounds that require new tissue formation. Transplantation of 
mesenchymal stem cells (MSCs) have been proposed to augment the reparative capacity of 
resident cells within the wound bed to help overcome complications in wound healing. However, 
MSCs face a variety of challenges within the wound microenvironment that hinder their survival 
post transplantation. Ischemia is considered one of the largest hindrances within the chronic wound 
microenvironment and has become a major focus for MSC therapies. MSCs are naturally pro-
angiogenic and numerous techniques have been attempted to improve their survival and efficacy 
post transplantation; many with little impact. These setbacks have prompted researchers to re-
examine the normal wound bed physiology, which have resulted in new MSC transplantation 
methods using extracellular matrix (ECM) proteins and hypoxia preconditioning. These studies 
have also led to new insight on associated intracellular mechanisms such as autophagy which plays 
a key role in further regulating MSC survival and paracrine signaling. This review provides a brief 
overview of cutaneous wound healing with discussion on how ECM proteins and hypoxia can be 










Appendix B.1 Introduction 
The skin is one of the largest organs of the body and plays an integral role in maintaining 
homeostasis with the world around us through three critical functions: regulation, protection, and 
sensation. Upon damage to the skin we can lose one or more of these functions and subsequently 
kick start the cutaneous wound healing machinery to restore balance. In most cases for patients 
who are young and healthy, there will be a successful wound resolution leading to restoration of 
normal skin functions. However, patients who are older or suffer from an array of diseases such as 
cardiovascular diseases, diabetes, or obesity have significantly higher impairment in their wound 
healing machinery. Currently in the United States 8.2 million Medicare beneficiaries require 
interventional wound treatments costing roughly $100 billion dollars1. The number of these 
patients is expected to increase over the next decade due to increasing age of the population 
compounded by the rise in comorbidities of chronic diseases.  
These challenges compromise the reserve or functioning of localized reparative cells, 
particularly in wounds that require new tissue formation. Mesenchymal stem cells, or multipotent 
stromal cells (MSCs), have been proposed as a treatment to augment the reparative capacity in 
patients needing a biological boost to their non-healing wounds. MSCs have become coveted for 
their pro-angiogenic and immune-modulatory properties in the regenerative medicine space. 
However, one major complication limiting the efficacy of MSCs are their poor survival rate post 
transplantation. This is due to the hostility of the wound microenvironment with ischemia being 
one of the most frequent challenges to overcome. This has led to the development of various 
strategies to improve MSC survival and angiogenic efficacy to overcome the ischemic barrier.  
While many of such approaches are pharmaceutical or genetic modifications to the MSCs 
themselves, several research groups have attempted to harness the physiological survival and 
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promotion signals native to a healthy wound healing microenvironment. Herein, we will focus on 
MSC combinational strategies utilizing matrix proteins and hypoxia as natural influences from the 
wound bed to augment survival and efficacy when used as exogenous cells to promote near 
regenerative cutaneous wound healing.  
 
Appendix B.2 Cutaneous Wound Healing 
Surface wounds are broken down into two major categories depending on the need for 
tissue regeneration during healing. Surgical wounds and simple cuts are restored by juxtaposing 
the open wounds edges together and closed mainly by localized matrix remodeling. However, 
when wounds, such as burns, abrasions and traumatic wounds present with lost tissue, a complex 
cascade of events ensue (Figure 32). An initial hemostatic and inflammatory phase limits the 
exposure to the external environment and restores a sterile barrier. This is followed through a tissue 
replacement phase and to successful resolution (scar). However, if complications occur during the 
early stages of healing with setbacks such as an insufficient immune response or hindered 
angiogenesis, then the wound will often become chronic or non-healing. Chronic wounds are 
defined as ulcers or open wounds that fail to resolve within 3 months and are further classified into 
three main subgroups: vascular ulcers, pressure ulcers, and diabetic ulcers 2, 3. The severity of 
chronic wounds will be unique for each patient and will need to be treated with a multifaceted 
approach by the clinicians. If unable to achieve wound healing advancement then patients run the 
risk of infection, further spreading of damaged tissue, and amputation. Due to the gravity of 
repercussions non-healing wounds present, this is the area where scientists and clinicians are most 
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focused on implementing new biological therapies. In contrast to chronic wounds, abnormalities 
in the last two stages of wound healing can result in a wound with excessive scarring such as keloid 
or hypertrophic scar3,4, 5. While the wound appears epithelialized and ‘healed’, these scars are 
dysfunctional and have an underlying dermis that is disfigured and compromised. The improper 
healing in these scars result in wounds that close but are structurally weaker and prone to re-
ulceration. 
The complete wound healing cascade is triggered when an injury damages the dermal and 
subdermal layers of the skin. The subsequent wound healing response is an intricate orchestration 
of three overlapping phases of repair that encompass numerous cell types, signaling cascades, and 
microenvironment modifications to reach a successful resolution (Figure 32). There are three main 
phases of wound healing: the hemostasis / inflammation phase, the tissue replacement phase, and 
the resolution phase. The first phase of wound repair is the hemostasis / inflammation phase where 
first point of concern is to stop the bleeding of ruptured blood vessels while subsequently 
preventing pathogenic infection. Upon injury, a clotting cascade is activated where blood 
circulating platelets and enzymatic converted fibrin come together to form a fibrin clot and provide 
an early provisional matrix over the wounded area6. This fibrin clot is also biologically active 
playing a major role in signaling a localized immune response through the recruitment of pro-
inflammatory macrophages (M1) and leukocytes to prevent infection and clear the wound of 
cellular and extracellular debris.  
The next phase of wound healing, the tissue replacement phase, begins with the in-
migration of fibroblasts, endothelial cells, epidermal cells, and other progenitor cells into the 
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wound bed to initiate the rebuilding of the injured tissue. Fibroblasts begin producing the collagen 
3-rich granulation tissue as a temporary supportive matrix to replace the absent extracellular matrix  
Figure 35: Roles for MSCs during cutaneous wound healing 
The hemostasis/inflammation phase is heavily reliant upon the pro-inflammatory machinery for sterilizing 
the wound and clearing damaged ECM debris. MSCs help to orchestrate a healthy initial immune response 
that eventually will turn over into a pro-reparative response. Upon entering the tissue replacement phase, 
MSCs produce various growth factors and chemokines to initiate a massive arrival of tissue resident cell 
types that will begin to rebuild within the wound bed. The resolution phase is the final phase of wound 





(ECM); endothelial cells begin to create new blood vessels via angiogenesis; and the epidermal 
cells start to migrate underneath the scab to permanently seal the wound surface and restore the 
epidermis. At this point the wound is considered sterile and a transition occurs where pro-
inflammatory macrophages (M1) decline and are replaced by wound healing macrophages (M2). 
These M2 macrophages help to produce and modulate the granulated ECM and promote further 
vasculature repair.  
The resolution phase is the final repair phase where the provisional wound bed is replaced 
with a mature ECM, the excess blood vessels are pruned by up to 90%7, and any residual 
proliferation and migration signals are terminated and replaced with ‘stop’ signals such as those 
acting through CXCR3 8. The wound bed will start to contract as fibroblasts transdifferentiate into 
myofibroblast to reorganize and restructure the immature collagen 3 to mature collagen 1, restoring 
tensile strength back to the skin9. With every phase having a successful outcome, all that will 
remain will be a light scar to hint at what occurred. 
Appendix B.3 Mesenchymal Stem Cells in Wound Repair 
Mesenchymal stem cells, or multipotent stromal cells (MSCs), are characterized for their 
ability to self-renew, adhere to plastic, and differentiate into subsets of specialized cells 
particularly suited for the regeneration of mesenchymal tissues (adipocytes, osteoblasts, 
chondrocytes, and myoblasts)10-16. They are further defined by the International Society for Cell 
& Gene Therapy for expressing markers: CD73, CD90, and CD105; while also lacking the 
expression of markers CD14, CD19, CD34, CD45, CD11b, CD79a, and HLA-DR17. MSCs as a 
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cellular therapy has shown clinical benefit in several disease situations, though this has related to 
the immunosuppressive activities rather than tissue generation18, 19. Unfortunately, this approach 
has proven disappointing in wound repair despite success in pre-clinical animal models as the stem 
cells are lost rapidly from the wound bed. A more recent area of success using MSCs has been for 
angiogenesis and improved healing amongst different tissue types. This is due to the variety of 
trophic factors that MSCs have been found to secrete in context to their microenvironment18, 19. 
Still, to achieve any significant benefit, the MSCs must remain for the time scale of the wound 
healing phase, which run in the weeks. 
The use of MSCs to treat dysfunctional cutaneous wounds is considered particularly 
promising for a number of reasons. First, the immune-tolerant site of the skin can accommodate 
extended persistence of allogeneic cells. Second, skin being an externally accessible organ, 
repeated applications can be achieved non-invasively. In addition, the pro-reparative secretome of 
MSCs can be utilized in different phases of the wound healing process (Appendix B – Figure 32). 
This is an advantage over direct application of growth factors or other molecules as the wound bed 
consists of asynchronous areas of healing; where MSCs are environmentally adaptive and can 
produce an appropriate response for the transitioning phases of the wound bed to recreate the 
physiological situation. Such as in a normal skin wound, where endogenous subsets of hair follicle 
MSCs called dermal sheath cells help to repair/replace the injured dermal tissue. While MSCs 
from the subcutaneous fat tissue and blood supply help regulate early and mid-phase inflammation 
while also helping to restore dermal tissue20, 21.  
Upon infiltrating the wound, MSCs begin to secrete pro-inflammatory cytokines (CSF2, 
IL-6, IL-8, CCL2, CCL3) recruiting neutrophils and M1 converted macrophages to help degrade 
damaged tissue21, 22 (in the Hemostasis/Inflammation phase), but also regulating the overall 
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inflammatory response by limiting the number of activated T-cells, neutrophils, and 
macrophages21, 23-25. Upon transition into the Tissue Replacement phase, MSCs focus on secreting 
cytokines directed to the proliferation and migration of epithelial cells for re-epithelialization 
(EGF, KGF, HGF), directing new endothelial cells for angiogenesis (VEGFA, ANGPT1, PDGF-
BB), and stimulating fibroblasts to produced matrix proteins that later transition to a mature 
provisional matrix (FGF)21, 22, 26, 27. MSCs also direct the polarization of monocytes into pro-
reparative M2 macrophages (IL-4, IL-13, IL-10, TGF-B) to help clear remaining cellular debris 
and modify temporary matrix21, 24. In the Resolution phase, MSCs continue to regulate the matrix 
through secretion of MMPs and TIMPs, while also regulating the amount of collagen disposition 
through balancing TGF-B1 and TGF-B3 to prevent hypertrophic scarring27. These vital guiding 
functions are unique to MSCs because they express low levels of major histocompatibility complex 
class (MHC) II along and lack the MHC co-stimulatory molecules which are essential for immune 
cell activation (CD40, CD40L, CD80, CD86); allowing for their use in allogeneic transplant with 
a very low rate of rejection28.  
Appendix B.4 Hostile Wound Microenvironment Challenges MSC Survival  
Despite the potential benefits MSCs possess for regenerative therapies, their use must first 
overcome pro-apoptotic stressors within wounded tissue29. Younger and healthier patients have 
wound healing machinery and endogenous MSCs that work well enough to overcome these healing 
challenges. However, in patients who are older and suffer from diseases such as those with type 2 
diabetes or metabolic syndrome, their MSCs become more susceptible to apoptosis, increased 
levels of ROS accumulation, and increased mitochondrial deterioration. Rendering their MSCs too 
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dysfunctional30 to be able to overcome the stress of the wound bed ultimately limiting their 
effectiveness in the wound healing process. This is where the reliance on exogenous MSCs 
therapies from healthier and younger donors has come to light. However, the lack of survival of 
exogenously applied MSC in wounds has still been well documented in a variety of tissues, 
particularly the heart31, brain32, and kidney33. For the heart, a survival rate of 5% within a two-
week period post myocardial infarction (MI) treatment 31, and only a 1% survival rate one hour 
after injection into an ischemic kidney model 33. Even when using an immunodeficient mouse 
model, Toma et al. report having less than 0.44% survival of MSCs 4 days post MI 34. Even skin, 
where immune tolerance should present less barriers to MSC, is devoid of implanted MSCs within 
a week 35.  
The disparagingly low survival rates likely result from a variety of factors within the harsh 
wound microenvironment, such as the absence of trophic factors, a heightened inflammatory 
response, and an impaired vasculature 36, 37. These factors induce MSC death through a variety of 
mechanisms, including anoikis, ischemic reactive oxygen species (ROS), loss of growth factors, 
or increased signaling from death cytokines38.(Figure 33). Our lab has previously shown that 
MSCs are very susceptible to ROS and pro-inflammatory death inducing signaling complexes that 
occur within the wound bed 39. We have also shown that MSCs are metabolically glycolytic 40, so 
that nutrient deprivation within the wound bed is also potentially detrimental to MSC survival 41, 
42. Recent evidence regarding hypoxic/ischemic stress showed that severe hypoxia (<1% O2) drives 
mitochondrial dysfunction resulting in apoptosis or necrosis 41, 43. Despite numerous approaches 
to limit MSC death post transplantation whether through growth factor or drug preconditioning or 
genetic modifications 44; most efforts have had a limited impact on overall MSC survival. The 
death of the exogenously applied MSCs is in counterpoint to the survival of the endogenous MSCs. 
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Therefore, we can learn from the physiological adaptations and survival mechanisms of successful 
resolving wounds to develop pro-survival therapies for those who have a dysfunction of their own 
MSCs, the elderly and those with co-morbidities. 
 
Figure 36 MSCs face a steep challenge in the wound microenvironment 
Several factors are in play that will limit their survival and therapeutic capacity. The innate immune 
response is responsible for destroying any foreign pathogens, but their methods of destruction can be non-
discriminatory through their release of pro-inflammatory cytokines and reactive oxygen species (ROS). The 
insult will also cause tissue damage, leaving behind ECM debris that can result in a lack of support to cells 
in the area, resulting in cell death via anoikis. Injury to the wound bed can also cause blood vessels to be 
severed subsequently resulting in all damaged vasculature to be blocked off. This will cause the wound 
microenvironment to become ischemic leaving all cells to be with little to no oxygen or nutrients available. 
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Appendix B.5 MSC Delivery Strategies 
Cutaneous wounds requiring interventional treatment options are often complex and 
require a multidisciplinary approach both at the macro level and micro levels of care. Where macro 
levels of care would be considered more general hospital methods of treatment such as site off-
loading, compression bandages, and fluid control. Micro level of care would be anything using a 
biological treatment focused on improving the wound at the microenvironment level. There are 
many elements clinicians and scientists must consider when utilizing and developing MSC 
therapeutic strategies. Cell source is often a major consideration because there are multiple types 
of MSC derived lineages that can behave differently under varying circumstances. In addition, 
there are some sources of MSCs that are easier to extract and with greater numbers than with other 
locations of the body. The two most common sources of MSCs for clinical use are either derived 
from the bone marrow where 0.001-0.002% of cells harvested are MSCs; or from adipose tissue 
where MSCs are estimated to make up 1% of the total cell population45. Cell administration 
strategies is another key factor and will change depending on the patients wound severity and type. 
But overall the main goal of improving MSC survival percentages post transplantation remains a 
focal point for enhancing MSC efficacy in wound healing. Here we focus on two of the most 
promising approaches for improving MSC retention: extracellular matrix construct and hypoxic 
preconditioning. Both of these methods rely on the impact of environmental cues upon the MSCs 
to influence their behaviors rather than artificial micro manipulations such as gene editing 
techniques or pharmaceutical drugs. The overarching idea for these MSC delivery strategies are to 
utilize components native to the wound healing environment / repair mechanisms in order to 
reduce extraneous stress other more artificial methods may add to an already dysfunctional system. 
Both extracellular matrix compositions and hypoxia/ischemia are central aspects of the 
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inflammatory and tissue replacement phases of wound healing, and thus can be considered 
physiological mimics.  
Appendix B.6 Matrix Components for MSC Delivery 
The extracellular matrix is now appreciated as being just as important as the cells 
themselves during healing 3, 40. The ECM is not just the major support structure of each tissue, but 
the tension combined with bioactive moieties within the ECM largely influences how cells within 
the tissue function and behave. The ECM’s biochemical makeup, rigidity, and shape are being 
exploited to manipulate tissue replacement and wound healing across many applications. Using 
ECM constructs that either resemble or impute the native matrix environment could help in 
promoting more physiological healing. 
Collagen-1 is the most abundant ECM protein of the skin and is usually preferred for 
shovel-ready scaffolds. Collagen-1 is biocompatible, biodegradable, and can form highly 
organized 2-D and 3-D network like structures that allows it to incorporate a wide variety of 
biological components ranging from growth factors to matrix proteins to cells. Collagen-1 has 
been shown to improve MSC proliferation potential and prevent MSC anoikis through the binding 
of integrin receptors α2/β1, and α11/β146, 47. Collagen-1 is also able to increase osteogenic 
differentiation through higher cell adhesion and enhance activation of RHO-A in vitro 46. Another 
structural collagen, Collagen VI, has been used to enhance MSC proliferation and stemness for 
cartilage repair, while also displaying pro-survival capabilities in fibroblasts 48, 49. Thus, 
encapsulating MSCs within structural collagen may augment the delivery of viable MSCs. 
However, Collagen-1 signals wound maturation and resolution, and thus would be suppressive 
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during the early tissue replacement phase of healing; importantly collagen-1-dominant matrices 
limit angiogenesis 40.  
A more immature matrix is likely needed to promote regenerative healing 50. Previous work 
in our lab has shown that the matricellular protein Tenascin-C (TNC) possesses epidermal growth 
factor receptor-like (EGF-L) repeats that can interact with the EGF receptor (EGFR) on MSCs in 
a low affinity/high avidity interaction; this restricts EGFR activation to the plasma membrane 29,51. 
The prolonged sequestration of EGFR enhances pro-survival signals, via low level tonic ERK and 
AKT signaling 37,52. The addition of TNC to MSCs provides for survival of the transplanted cells 
for up to a month 26, 35. Given that TNC is found naturally during the early phases of wound healing, 
coupling it with MSCs as a therapeutic delivery system is expected to not only provide for 
enhanced survival but also improve healing 26, 35. Laminin V is another promising immature matrix 
protein that contains cryptic EGFR matrikines52. Combinational strategies using Laminin with 
MSCs have shown to enhance overall survival and improve wound healing outcomes through 
upregulated angiogenic capacity in diabetic rats and other models53, 54. The wound response matrix 
component fibronectin is another top candidate for MSC delivery. MSCs survival was enhanced 
in a rat hind limb model when encapsulated in agarose capsules containing fibronectin and 
fibrinogen pro-survival signals55, in addition to increasing proangiogenic capacity of MSCs in 
vitro54.   
In addition to improving MSC survival and paracrine signaling, many of these immature 
matrices also promote the migration of cells around the wound bed. Tenascin-C, laminin, 
fibronectin, and thrombospondin all play vital roles in orchestrating the movement of distal 
proliferating resident cells to the center of the wound bed mainly through integrin binding 
mechanisms56-58. These properties add another facet to the overall capability of these MSC-ECM 
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combinational therapies. Where the immature matrices improve the survival and growth factor 
secretion of MSCs, which then promotes enhanced proliferation of the resident tissue cells, that in 
turn are able to migrate into the wound quicker due to the aforementioned present immature matrix. 
Further adding to this enhanced cycle of repair, MSCs have also shown that they can deposit ECM 
proteins such as fibronectin, tenascin-C, thrombospondin and others59. All together these 
matricellular proteins are highly regulated in adult tissues with restricted expression to areas of 
active remodeling, such as in wound healing 60. Thus, by following the lessons from physiological 
healing, novel approaches can be designed employing the same matricellular proteins. 
Appendix B.7 Hypoxic Preconditioning for MSC Delivery 
Many MSCs reside in areas of low oxygen-tension from 3-9% depending on the tissue 
source 61, 62. Hypoxia within the stem cell niche is thought to maintain self-renewal, proliferation, 
migration, and ultimately appears to augment their therapeutic potential 63-65. Taking these cues 
from physiology, this has led to experiments in which MSCs are grown at similarly low levels of 
oxygen to condition or acclimate them prior to wound implantation. However, when oxygen levels 
reach extreme levels of hypoxia (<1.5% O2) such as within a wound bed, MSCs can become over 
stressed and undergo apoptosis 64. Further studies have shown that MSCs are innately glycolytic 
40, and it is the combination of low oxygen tension and nutrient deprivation within the ischemic 
wound environment that severely challenges the cells. MSCs exposed to near-anoxic conditions 
(0.1% O2) for as little as three days were shown to rapidly consume all internal glucose energy 
reserves resulting in poor survival post implantation 66.  
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With both oxygen and nutrients being vital for MSC survival post implantation, researchers 
are focused on creating delivery methods that improves at least one of these bioenergetic 
challenges. The biggest and potentially easiest way to enhance MSC survival is to pre-condition 
MSCs in hypoxic conditions (1-4% O2) for 24 to 48 hours prior to implantation. MSCs pre-exposed 
to these hypoxic conditions respond by upregulating the hypoxia inducible factor 1α (HIF-1α) 67. 
HIF-1α is a major regulator and response factor to oxygen tension within the cell, in which it will 
be post-translationally modified and marked for degradation under normal oxygen conditions. 
During hypoxia, HIF-1α escapes degradation and translocates to the nucleus where it will then 
activate hypoxia response elements (HREs). Many of the genes that HREs target are involved in 
promoting angiogenesis (i.e. Vascular endothelial growth factor, VEGF), survival (Bcl-2, AKT), 
or regulate metabolism via increasing glycolytic potential (i.e. glucose transporter 1 - GLUT1, 
lactate dehydrogenase A – LDHA, phosphoglycerate kinase 1- PGK1) 68, 69. The increase in 
glycolytic genes translates to increased MSC consumption of glucose and production of lactate in 
an oxygen-dependent manner 64, 70. Further analysis of HRE targets genes have also found active 
mitochondrial repressors such as pyruvate dehydrogenase kinase 1 (PDK1); an inhibitor of 
pyruvate entrance into the TCA cycle. PDK1 inhibition of pyruvate effectively reduces 
mitochondrial oxygen consumption and thus allows cells to preserve their intracellular oxygen 
concentrations 71. MSCs exposed to hypoxic conditions also utilize HIF-1α to activate the AKT 
signaling pathway to enhance survival and proliferation 72. However, when HIF-1α is knocked-
down, compensatory activation of the p53 pathway occurs resulting in a higher induction of 
apoptosis 69. These manipulations appear to marginally improve the survival of the transplanted 
MSCs70, 73.Thus, the next steps would be a combination of hypoxic preconditioning with delivery 
within matricellular components such as TNC. 
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Appendix B.8 Autophagy May Be Key Mechanism for Survival and Efficacy in MSC 
Combinatorial Therapy  
Upon further investigation into the effects of hypoxic preconditioning on MSCs, 
upregulated HIF-1α was shown to promote the initiation of macroautophagy 74. Macroautophagy 
(hereafter, autophagy), is an evolutionarily conserved “self-eating” catabolic process that targets 
cellular components for degradation through the formation of double membraned organelles called 
autophagosomes that later fuse with lysosomes 75. Under normal circumstances, autophagy is a 
highly selective process used to maintain cellular homeostasis by degrading the buildup of 
aggregate-prone proteins and dysfunctional organelles 76. However, when cells are exposed to 
environmental stressors such as nutrient deprivation or hypoxia, autophagy becomes a non-
selective process indiscriminately sequestering large amounts of cytosolic cargo for degradation 
in the attempt to prolong survival 77. The activation of non-selective autophagy quickly becomes 
a balancing act within a cell, as autophagy can play a role in both cell survival and apoptosis 78. In 
addition, autophagy and apoptosis mutually inhibit each other until an undefined sensitivity 
threshold is reached and one process overtakes the other; subsequently resulting in either 
adaptation of the cell to the stress or stressed induced death 43, 79. It is through these threshold 
boundaries where MSCs can be further fine-tuned to escalate their efficacy as cell therapies.  
MSC performance and function are tied to its ability to regulate autophagy80. To date, basal 
autophagy levels have been shown to be higher in MSC populations compared to differentiated 
cell types 81. Additional studies suggest that autophagy is required for conservation of MSC 
stemness and self-renewal capabilities 82. Even more interesting is that non-stressed MSCs 
accumulate arrested autophagosome, and their autophagic manipulation significantly alter the 
balance between renewal and differentiation 83. MSC directed differentiation dynamics will change 
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when autophagy is manipulated as early as 3 hours after induction into adipogenic and osteogenic 
lineages 83, 84. This is due to the MSCs quickly consuming the arrested autophagosomes that were 
present prior to induction, and by speeding up or slowing down the autophagy process, this will 
either increase or decrease the overall differentiation efficiency outcomes 83.  
MSC paracrine function has also been linked to autophagic manipulation. This has been 
reported mostly in conjunction with hypoxic preconditioning. As MSCs experience hypoxia, HIF-
1α becomes upregulated and allowed to translocate into the nucleus, it initiates the production of 
BNIP3/BNIP3L, a set of pro-autophagy proteins that interact with the Bcl-2 sequestration complex 
allowing Beclin-1 to dissociate away and initiate the autophagic cascade 85. In addition to BNIP3, 
hypoxia also positively influences autophagy induction through regulating the expression of 
MAP1LC3β and ATG5 via PERK-UPR pathway, as well as activating the AMPK pathway 86. This 
upregulation in autophagic flux has been linked to increased expression of VEGF secretion through 
direct phosphorylation of ERK 87.The combination of pretreating MSCs with hypoxia could 
enhance the therapeutic potential of MSCs even further especially by promoting angiogenesis 88. 
In treating post MI hearts, MSCs that underwent hypoxic preconditioning exhibited higher rates 
of autophagic flux resulting in higher retention in cell number and a significant reduction in scar 
formation within the infarct wall 89.  
The strong connection of autophagy to cellular processes such as angiogenesis has 
launched the cancer treatment and stem cell therapy fields to find additional upstream 
activation/regulation inputs. This has resulted in a large emphasis on the ECM as a point of interest 
for such studies90. The most recent studies have focused on proteoglycans, primarily the small 
leucine rich proteoglycan called Decorin91, 92. Decorin becomes upregulated within the resolution 
phase of wound healing where mature matrix such as Collagen-1 becomes present again during 
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this final stage of healing. Decorin is considered an important shut off switch for the pro-reparative 
mechanism of the tissue replacement phase, as it binds to growth factor receptors such as EGFR, 
VEGFR2, and MET; and limits the occurrence of hypertrophic scarring through preventing 
excessive repair. Upon binding these receptors, Decorin will induce autophagy and mitophagy 
responses within the cell91, 93. However, these actions have been shown in differentiated cells and 
not yet in stem cells. It is also unclear of the physiological roles Decorin induced autophagy has 
in certain cell types91. When postulating what this could mean for MSCs, Decorin could be helping 
to reset the stem cell niche back to its dormant state by downregulating the proliferation and 
angiogenic signals once needed for early wound repair. And like other cells that remain in a 
quiescent state for long periods of time, they rely heavily on autophagy to clear out unwanted 
intracellular debris unlike higher proliferating cell types. 
For early wound healing situations, The immature matricellular TNC has been linked to 
prompt Beclin-1 induction94 which could possibly induce autophagic flux. This would either be a 
second mode of survival mechanism (in addition to the tonic AKT and ERK signaling) or an 
additional driver in producing the secretome for tissue replacement. TNC is also known as being 
an anti-adhesive matrikine, allowing for the migration and ECM detachment of cells during 
development and wound repair94. Loss of ECM attachment has been shown to induce autophagy 
to promote a survival mechanism against short term anoikis95. Thus, the anti-adhesive nature of 
TNC along with other ECM anti-adhesive glycoproteins could render a secondary method of action 




Figure 37: MSC-ECM combinational strategies need to be customized 
Depending on the target stage of wound healing MSC will have different intracellular influences on 
performance. The left panel represents an MSC-ECM combinational therapy targeting the inflammatory 
and tissue replacement phases of wound healing such as in treating a chronic ulcer. Using a matrix protein 
that is naturally occurring during the early phases of wound repair, TNC will provide pro-survival signals 
through continual ERK and AKT signaling cascades. In conjunction with the TNC survival signals, the 
MSCs will be exposed to hypoxia/ischemia. This will jump start the HIF-1α signaling complex and result 
in an upregulated autophagic (BNIP3) and pro-angiogenic response (Hypoxia Response Elements such as 
VEGFA). TNC is also linked to the induction of Beclin1 and has been postulated as an influencer of 
autophagic expression. With the addition of the autophagic machinery the MSCs can utilize its output of 
nutrients / building blocks (amino acids, nucleic acids, fats, sugars) to further enhance its pro-angiogenic 
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(Continued) signaling properties. In the right panel we have an MSC-ECM combinational therapy that 
would be used to target the resolution phase of wound healing in hopes of stopping excess scar formation. 
Decorin is a naturally occurring matrix protein during the resolution phase and works as a major stop signal 
for all the pro-wound healing systems that were at play in the early phases of repair. It binds to various 
growth factors and receptors where it signals the surrounding cells to stop proliferating (EGF), and stop 
producing angiogenic factors (VEGFR2, MET, EGFR). However, Decorin is well known for inducing a 
robust induction of autophagy (VEGFR2) without a real clear understanding of how that effects the 
physiology of the cells moving forward. 
 
majority of these anti-adhesive ECM proteins to be properly combined with MSC delivery 
strategies in 2D or 3D, Col-1 is often used has a structural tether to keep everything together. 
However, there is evidence in vitro that Col-1 actively down regulates autophagy96, suggesting 
that further research will be needed to fine tune the ratio of matrix protein delivery strategies 
depending on the required outcome. This concept is even more important when considering what 
phase of wound healing is needing to be targeted. Where a pro-survival ECM protein like TNC is 
useful during the inflammation and tissue replacement phases of repair to help restore delayed 
wound healing; and Decorin is most useful during the resolution phase of wound healing to stop 
the pro-reparative system from over producing and creating unwanted scarring (Figure 34). 
Altogether, both environmental stimuli of hypoxic preconditioning and matrix proteins are linked 
to autophagy in various ways, and further investigation into how to finetune their inputs in 
conjunction with autophagic flux could prove to be a key insight into optimizing MSC therapeutic 
approaches. Especially in essential processes such as angiogenesis, where increased autophagic 
flux has been linked to upregulating angiogenesis through increased production of VEGFA in 
cutaneous wound repair87.  
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Appendix B.9 Conclusion 
MSCs have numerous attributes that make them attractive for facilitating healing in 
dysfunctional and nonfunctional wound beds. Their use as adaptive paracrine and matrix 
producing ‘factories’ is desirable in that eventually rejected allogeneic cells could still promote 
near-regenerative healing. However, MSCs face many challenges post transplantation into the 
wound bed. Overcoming these challenges is necessary to demonstrate their efficacy in treating 
injured tissue (Figure 35). We propose that successful use of MSCs in promoting more 
regenerative healing or completing stalled chronic wounds will ensue from learning from the 
physiology. Using preconditioning techniques and matrix support strategies to target autophagic 
responses could be a key in improving MSC survival80. MSCs are inherently glycolytic40 and will 
rapidly use internal energy reserves 66 when subjected to extreme environments such as ischemia 
in wound bed. Manipulating how MSCs utilize autophagic flux could help maintain internal energy 
stores for longer period of time, leading to larger cell retention. Matricellular component-
containing delivery vehicles not only impact autophagy and metabolic programming but also 
directly trigger survival pathways, further improving the persistence of transplanted MSCs. This 
increase in survival fraction would allow for the MSCs to exert trophic influences on angiogenesis 





Figure 38: Overview schematic of combinational MSC therapies 
First step in the process is to prepare the ECM constructs and MSCs for delivery. The type of skin wound, 
and the build of the ECM scaffold will determine whether MSCs need to be combined with the ECM before 
or after hypoxic preconditioning takes place. Once the MSC-ECM sample has been prepped, they can be 
delivered to the wound. The combination of the ECM construct support and the hypoxic preconditioning 
will help the MSCs overcome the initial shock of the ischemic wound bed, allowing them to acclimate 
better to newly encountered cellular stressors. The ischemic environment will promote additional 
intracellular survival machinery such as autophagy, allowing the MSCs to gain additional nutrients and 
energy for longer survival. Once the MSCs have stabilized, they will start to respond to the ischemic 
environment by utilizing the autophagy machinery and produce pro-angiogenic growth factors such as 
VEGF to promote angiogenesis. The restoration of new vessels will help enrich the surrounding resident 
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Appendix C – Antibodies 




Collagen I  Abcam  ab34710 RRID:AB_731684 
MITF antibody [D5] Abcam ab3201 RRID:AB_303601 
Tenascin C antibody [EPR4219] Abcam ab108930 RRID:AB_10865908 
E-Cadherin (24E10)  
Cell Signaling 
Technology 3195 RRID:AB_2291471 
GAPDH (D16H11)  
Cell Signaling 















p44/42 MAPK (Erk1/2)  
Cell Signaling 
Technology 9102 RRID:AB_330744 
α-Tubulin Antibody 
Cell Signaling 
Technology 2144 RRID:AB_2210548 
α-Tubulin (DM1A)  
Cell Signaling 
Technology 3873 RRID:AB_1904178 
Decorin  R&D Systems  AF143  RRID:AB_354790 
Tenascin-C Antibody (BC-24) 
Santa Cruz 
Biotechnology sc59884 RRID:AB_785991 
α-Smooth Muscle, Anti-Actin Sigma-Aldrich A5228 RRID: AB_262054 
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Appendix D - Chemicals & Reagents 
Table 5: Chemicals and Reagents 
CHEMICALS SOURCE PRODUCT # 
Vemurafenib (PLX4032) Selleck Chemicals CAT# S1276 
Selumetinib (AZD6244) Selleck Chemicals CAT# S1008 
Vactosertib (TEW-7197)  Selleck Chemicals CAT# S7530 
Infigratinib (BGJ-398) Selleck Chemicals CAT# S2183 
PD153035 (EGFRi) Selleck Chemicals CAT# S1079 
SB431542 (TGFβRi) Selleck Chemicals CAT# S1067 
Alexa Fluor 488 Phalloidin Thermo Scientific  CAT# A12379 
Alexa Fluor 594 Phalloidin Thermo Scientific  CAT# A12381 
Collagen I - High Concentration Rat Tail Corning  CAT# 345249 
Goat Anti-Rabbit IgG Antibody, HRP-conjugate Sigma Aldrich CAT# 12-348 
Goat Anti-Mouse IgG Antibody, HRP-conjugate Sigma Aldrich CAT# 12-349 
   
REAGENTS SOURCE PRODUCT # 
Control Lenti particles - GFP     Origene 
CAT# 
TR30021V 






Appendix E – Primers 
Table 6:  Primers 
GENE 
PrimerBank 
or REF ID   
Sequence (5' -> 3') 
      
TGFβ1 (version 1)  260655621c1  Forward GGCCAGATCCTGTCCAAGC 
    Reverse GTGGGTTTCCACCATTAGCAC 
TGFβ1 (version 2)  260655621c2 Forward CTAATGGTGGAAACCCACAACG 
    Reverse TATCGCCAGGAATTGTTGCTG 
TGFβ2 (version 1)  305682568c2 Forward CCCCGGAGGTGATTTCCATC 
    Reverse GGGCGGCATGTCTATTTTGTAAA 
TGFβ2 (version 2)  305682568c3 Forward CCATCCCGCCCACTTTCTAC 
    Reverse AGCTCAATCCGTTGTTCAGGC 
TGFβR1 (version 1)  195963411c2 Forward GCTGTATTGCAGACTTAGGACTG 
    Reverse TTTTTGTTCCCACTCTGTGGTT 
TGFβR1 (version 2)  195963411c3 Forward CACAGAGTGGGAACAAAAAGGT 
    Reverse CCAATGGAACATCGTCGAGCA 
TGFβR2 (version 1)  133908633c2  Forward AAGATGACCGCTCTGACATCA 
    Reverse CTTATAGACCTCAGCAAAGCGAC 
TGFβR2 (version 2)  133908633c1  Forward GTAGCTCTGATGAGTGCAATGAC 
    Reverse CAGATATGGCAACTCCCAGTG 
TNC (version 1)  340745336c2  Forward GCCCCTGATGTTAAGGAGCTG 
    Reverse GGCCTCGAAGGTGACAGTT 
TNC (version 2)  340745336c3 Forward AGGGCAAGTGCGTAAATGGAG 
    Reverse TGGGCAGATTTCACGGCTG 
JUN (version 1)  44890066c1 Forward TCCAAGTGCCGAAAAAGGAAG 
    Reverse CGAGTTCTGAGCTTTCAAGGT 
JUN (version 2)  44890066c2 Forward AACAGGTGGCACAGCTTAAAC 
    Reverse CAACTGCTGCGTTAGCATGAG 
MCP1 4506841a1  Forward CAGCCAGATGCAATCAATGCC 
    Reverse TGGAATCCTGAACCCACTTCT 
TGFA 345842399c1  Forward AGGTCCGAAAACACTGTGAGT 
    Reverse AGCAAGCGGTTCTTCCCTTC 
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Table 6: Continued    
EGFR (version 1)  41327735c2 Forward CCCACTCATGCTCTACAACCC 
    Reverse TCGCACTTCTTACACTTGCGG 
EGFR (version 2)  41327735c3 Forward TTGCCGCAAAGTGTGTAACG 
    Reverse GTCACCCCTAAATGCCACCG 
IL2 (version 1)  28178861a2 Forward TCCTGTCTTGCATTGCACTAAG 
    Reverse CATCCTGGTGAGTTTGGGATTC 
IL2 (version 2)  28178861a1 Forward AACTCCTGTCTTGCATTGCAC 
    Reverse GCTCCAGTTGTAGCTGTGTTT 
IL6 (version 1)  224831235c1 Forward ACTCACCTCTTCAGAACGAATTG 
    Reverse CCATCTTTGGAAGGTTCAGGTTG 
IL6 (version 2)  224831235c2 Forward CCTGAACCTTCCAAAGATGGC 
    Reverse TTCACCAGGCAAGTCTCCTCA 
CXCL10  323422857c1 Forward GTGGCATTCAAGGAGTACCTC 
    Reverse TGATGGCCTTCGATTCTGGATT 
MMP1 221004045 Forward ACACCTCTGACATTCACCAAG 
  221004046 Reverse ATGAGCCGCAACACGATG 
ACTA2 (version 1)  16305849 Forward CAGATGTGGATCAGCAAACA 
  221004048 Reverse TGGCTAGGAATGATTTGGAA 
ACTA2 (version 2)  22100451 Forward GTGTGTGACAATGGCTCTGG 
  22100452 Reverse TGGTGATGATGCCATGTTCT 
VIM 221004949 Forward CAGGAGTCCACTGAGTACCG 
  16305849 Reverse CGGCCAATAGTGTCTTGGTA 
PDL1 16184116 Forward TCACTTGGTAATTCTGGGAGC 




Appendix F - Cell Lines 
Table 7: Primary cells and cell lines 
Sample ID SOURCE 
Mutational 
status Site of resection 
Pre-op 
Treatment Age/sex Status 
TP-12 293 UPCI BRAFV600E Brain, metastatic Vemurafenib 53, NA Deceased 
TP-0004 AHN NA Skin, cutaneous PD1 85, M Alive 
TPF-50236 Adjacent This study NA Skin, cutaneous unknown 73, M unknown 
TPF-50236 Distant This study NA Skin, cutaneous unknown 73, M unknown 
TPF-50236 Adjacent This study NA Skin, cutaneous unknown 36, M unknown 
TPF-50236 Distant This study NA Skin, cutaneous unknown 36, M unknown 
       
       
Cell Line SOURCE PRODUCT # Mutational status Accession Age/sex  
A375 ATCC CRL-16919 
BRAF V600E 
CDKN2A 





















0001 BRAFV600E (+/-) CVCL-6785 NA, M  
THP-1  ATCC  TIB-202 
NRASG12R (+/-); 
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